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Cognitive enhancerPathological fear and anxiety are highly debilitating and, despite considerable advances in psychotherapy
and pharmacotherapy they remain insufﬁciently treated in many patients with PTSD, phobias, panic and other
anxiety disorders. Increasing preclinical and clinical evidence indicates that pharmacological treatments
including cognitive enhancers, when given as adjuncts to psychotherapeutic approaches [cognitive behavioral
therapy including extinction-based exposure therapy] enhance treatment efﬁcacy, while using anxiolytics
such as benzodiazepines as adjuncts can undermine long-term treatment success. The purpose of this review
is to outline the literature showing how pharmacological interventions targeting neurotransmitter systems
including serotonin, dopamine, noradrenaline, histamine, glutamate, GABA, cannabinoids, neuropeptides
(oxytocin, neuropeptides Y and S, opioids) and other targets (neurotrophins BDNF and FGF2, glucocorticoids,
L-type-calcium channels, epigenetic modiﬁcations) as well as their downstream signaling pathways, can aug-
ment fear extinction and strengthen extinctionmemory persistently in preclinicalmodels. Particularly promising
approaches are discussed in regard to their effects on speciﬁc aspects of fear extinction namely, acquisition,
consolidation and retrieval, including long-term protection from return of fear (relapse) phenomena like
spontaneous recovery, reinstatement and renewal of fear. We also highlight the promising translational value
of the preclinial research and the clinical potential of targeting certain neurochemical systemswith, for example
D-cycloserine, yohimbine, cortisol, and L-DOPA. The current body of research reveals important new insights into
the neurobiology and neurochemistry of fear extinction and holds signiﬁcant promise for pharmacologically-
augmented psychotherapy as an improved approach to treat trauma and anxiety-related disorders in a more
efﬁcient and persistent way promoting enhanced symptom remission and recovery.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).in; AC, adenylate cyclase; AMPA,α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AMY, amygdala; BA, basal amygdala;
mygdaloid complex; BZD, benzodiazepine; CaMKII, Ca2+/calmodulin-dependent protein kinase II; cAMP, 3′-5′-cyclic adenosine
1C isoform; Cav 1.3, L-type calcium channel alpha 1D isoform; CBT, cognitive behavioral therapy; CCK, cholecystokinin; CeA,
olateral amygdala; CNS, central nervous system;CREB, cAMPresponse element binding; CS, conditioned stimulus;DA, dopamine;
genous cannabinoiod; ERK, extracellular regulated kinase; ERP, exposure and prevention CBT; FGF2, ﬁbroblast growth factor-2;
, generalized anxiety disorder; GAD (65/67), glutamate decarboxylase 65/67; GluN, NMDA receptor subtype; GR, glucocorticoid
AT, histone acetyltransferase; HDAC, histone deacetylase; HDAC2, histone deacetylase 2; HPA, hypothalamic–pituitary–adrenal
nfralimbic cortex; ITC, intercalated cell masses; K, lysine; KOR, kappa opioid receptor; LA, lateral amygdala; L-DOPA, levodopa;
thylenedioxy-N-methylamphetamine; Mg2+, magnesium ion; mGluR, metabotropic glutamate receptor; miRNA, micro-RNA;
cleic acid; MS-275, entinostat (Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl] phenyl]methyl]carbamate); NMDA, N-
died; NO, nitric oxide; NPS, neuropeptide S; NPY, neuropeptide Y; OCD, obsessive-compulsive disorder; OXT, oxytocin; PAG,
ethylthio]-2,6-diﬂuorophenoxyacetamide; PKC, as Ca2+ /phospholipid-dependent protein kinase C; PTSD, post-traumatic stress
; SAHA, vorinostat (N-hydroxy-N′-phenyl-octanediamide); SNP, single nucleotide polymorphism; SNRI, selective noradrenaline
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Fear, anxiety and trauma-related disorders are associated with ex-
cessive fear reactions triggered by speciﬁc objects, situations or internal
and external cues in the absence of any actual danger, and often include
an inability to extinguish learned fear and to show adequate safety
learning [(Jovanovic et al., 2012; Michael et al., 2007; Milad et al.,
2009; Milad et al., 2013; Wessa & Flor, 2007) reviewed in (Holmes &
Singewald, 2013) and (Kong et al., 2014)]. Pathological fear and anxiety
occur in a range of psychiatric conditions, including various types of
phobia (e.g. social phobia, agoraphobia or speciﬁc phobia), panic disor-
der with/without agoraphobia, obsessive–compulsive disorder (OCD),
generalized anxiety (GAD) and post-traumatic stress disorder (PTSD)
(DSM-5, 2013; ICD-10, 1994). These disorders comprise the most com-
mon mental disorders and are estimated to have a life-time prevalence
of up to 28% among western populations (Kessler et al., 2005; Kessler
et al., 2012; Wittchen et al., 2011). In addition to the personal suffering
of patients, the economic burden caused by anxiety disorders is heavy
(Gustavsson et al., 2011).
Available pharmacological and psychotherapeutic treatments
(Bandelow et al., 2007) which aim to reduce fear and anxiety are asso-
ciated with decreased symptom severity, but up to 40% of anxiety pa-
tients show only partial long-term beneﬁt, and a majority of them fail
to achieve complete remission (Bandelow et al., 2012; Hoffman &
Mathew, 2008; Stein et al., 2009) clearly underlining the need for fur-
ther improvement. Current pharmacological approaches either induce
rapid anxiolytic effects (e.g. benzodiazepines, some antipsychotics) or
require prolonged, chronic treatment (e.g. antidepressants) to attenu-
ate symptoms of pathological fear and anxiety. Commonly employed
psychotherapeutic interventions apply cognitive behavioral strategies
and exposure techniques to help patients overcome the maladaptive
beliefs and avoidance behaviors that reinforce the pathology related
to fear-eliciting cues. Meta-analyses show that cognitive behavioral
therapy (CBT) does have efﬁcacy for several anxiety disorders, including
PTSD, but patients have difﬁculty bearing the demanding and
exhausting process of therapy and many who do manage to cope with
it respond only partially and often relapse with time (Choy et al., 2007).
One strategy to improve CBT is to augment psychotherapy with ad-
junctive pharmacological treatments. Early attempts at combining ‘CBT’
with anxiolytic medications [e.g. benzodiazepines (BZD)] showed that
the combination was no more effective [in some instances even coun-
terproductive (Marks et al., 1993; Wilhelm & Roth, 1997)] than
psycho- or pharmacotherapy alone [for details see (Dunlop et al.,
2012; Hofmann, 2012; Otto et al., 2010a,b; Rodrigues et al., 2011)].
However, at least in some cases, this failuremay have reﬂected idiosyn-
cratic effects of the drugs tested (especially BZDs) rather than utility of
the strategy itself, and there has been an intense search to identify
agents that serve as more effective adjuncts to CBT. The preclinical
assay most frequently used in this search is fear extinction — the focus
of this current review. Extinction of fear following Pavlovian fear learn-
ing (Pavlov, 1927) in animals is procedurally similar to exposure-based
CBT (Milad & Quirk, 2012). We will brieﬂy outline different aspects of
Pavlovian fear learning [(which is thought to be involved in the etiologyandmaintenance of anxiety disorders, e.g. (Amstadter et al., 2009)] and
extinction highlighting the key processes that could be targeted to
augment fear extinction (see Fig. 1 for an overview).
1.1. Fear and fear extinction
Experimentally, fear conditioning occurs when a previously neutral
stimulus [conditioned stimulus (CS) — such as a tone or light] is paired
with an aversive, unconditioned stimulus (US— e.g. electric shock to the
forearm in humans, mild foot shock in rodents), resulting in a CS–US
association whereby the CS alone elicits a conditioned fear response
(e.g. freezing in rodents or increased skin conductance in humans).
Following a successful CS–US association, fear memories require consoli-
dation, a process involving a cascade ofmolecular and cellular events that
alter synaptic efﬁcacy, aswell as a prolonged systems level interaction be-
tween brain regions, to stabilize the memory (McGaugh, 2000). Once
consolidated, fear memories, reactivated by presenting the CS, are de-
stabilized to render the original fear memory liable to pharmacological/
behavioral interference (see overview in Fig. 1) and this is then
followed by a second phase of molecular and cellular events to re-
stabilize (re-consolidate) the (adapted) memory (Nader et al., 2000).
Fearmemories can be attenuated by various processes and interven-
tions (including pharmacological and psychological approaches), some
producing temporary blunting of fear behaviors and others causing
more long-lasting relief. Interfering with the re-consolidation by
inhibiting molecular and cellular events supporting fear memory re-
stabilization [Fig. 1C, (Lee et al., 2006; Nader et al., 2000)], for example
with β-adrenoceptor blockers (Debiec & Ledoux, 2004; Kindt et al.,
2009), has been proposed as a clinical approach to alleviating fearmem-
ories. For discussion on this and othermeans of reducing fear (e.g. via US
habituation) we refer the reader to some excellent prior reviews
(Graham et al., 2011; Schwabe et al., 2014). Other potential ways to
relieve fear include safety learning (Kong et al., 2014; Rogan et al.,
2005) and erasure-like mechanisms such as destruction of erasure-
preventing perineuronal nets (Gogolla et al., 2009).
Alternatively, fear memories can also be extinguished. Fear extinc-
tion, a process originally described by Pavlov (Pavlov, 1927), entails re-
peated exposure to anxiety-provoking cues to establish a newmemory
that counters the original fearmemory. The process is highly relevant to
fear, anxiety and trauma-related disorders which are associated with
negative emotional reactions triggered by speciﬁc objects, situations
or internal and external cues that are excessive to the actual danger
posed. Moreover, extinction in animals is procedurally similar to
forms of CBT that rely on exposure to anxiety-provoking cues (see
Fig. 1) (Milad & Quirk, 2012), and anxiety disorders are associated
with an inability to extinguish learned fear and to respond adequately
to safety signals (Jovanovic et al., 2012; Michael et al., 2007; Milad
et al., 2009; Milad et al., 2013; Wessa & Flor, 2007) [reviewed in
(Holmes & Singewald, 2013)]. Thus, fear extinction has considerable
translational utility. The key processes that can be targeted to pharma-
cologically augment fear extinction are summarized in Fig. 1.
Extinction is a learning process driven by violation of the original
CS=US contingency (termed ‘prediction error’ for review see (Pearce
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Fig. 1. Different modes of fear alleviation and sites of possible pharmacological intervention. A, Fear alleviation is mediated via different mechanisms leading to acute or sustained fear
relief. Sustained fear relief can be obtained either with exposures to the feared cues/situations or, in some instances, also without them. For a detailed description of the involved mech-
anisms, see Riebe et al. (2012). Pharmacological interventions to boost fear relief can target different mechanisms at various levels. Examples are given with numbers 1–4, for detail see
text. B, Fear conditioning represents a training phase in which a novel conditioned stimulus (CS) is paired with an unconditioned stimulus (US) (redline). Throughout fear training and
testing, fear is measured as a conditioned response (y-axis), typically freezing, fear-potentiated startle, increased heart rate, and other quantiﬁable behavioral measures of fear. Following
this training period,mice undergo a consolidation phase which transfers the labile newly formed fear memory into a stable long-termmemory. Fear can be extinguished by repeated pre-
sentations of the CS (without the US; red line) resulting in fear extinction. Following the extinction training session, and akin to fear learning, consolidation processes are initiated to sta-
bilize this labile fear extinctionmemory into a long-termmemory. Poor extinction is evidenced by high fear responding (red bar), and successful extinction retrieval is shown by reduced
fear (green) during a retrieval test. Extinguished fear can recover via three mainmechanisms: spontaneous recovery (recovery of extinguished fear responses occurs with the passage of
time in the absence of any further training), fear renewal (when the conditioned CS is presented outside the extinction context, for example the conditioning or novel contexts), and fear
reinstatement (when un-signaled presentations of the US are interposed between the completion of extinction training and a subsequent retention test). Drugs (green arrows) can be
administered either immediately prior to (to induce extinction acquisition also called ‘within-session extinction’ and/or extinction consolidation) or immediately following (to rescue/
boost extinction consolidation processes) the training session to modulate extinction mechanisms. A clinical aim of drug augmentation strategies is to promote good extinction retrieval
and to protect against return-of-fear phenomena to provide good ‘longterm extinction’. C, Fear memory can be reactivated (red bar) by presentation of the CS, which transfers the stabi-
lized memory into a labile phase which requires reconsolidation (a process by which previously consolidated memories are stabilized after fear retrieval). The fear memory can then be
tested during another retrieval test (red bar) to assess reconsolidation. Drugs (green arrow) can be administered either immediately prior to or after the retrieval session to modulate
reconsolidation mechanisms. This effect can then be tested during subsequent retrieval tests. Evidence for successful interference with reconsolidation of the original fear memory is re-
vealed in reduced freezing during the test session.
152 N. Singewald et al. / Pharmacology & Therapeutics 149 (2015) 150–190&Bouton, 2001;McNally &Westbrook, 2006)], but it also contains other
elements including habituation and desensitization some also say era-
sure/destabilization (Lin et al., 2011). Some authors therefore favor
the term ‘relearning’ over extinction [for discussion see (Riebe et al.,
2012)]. As with fear learning, extinction occurs in two phases:
extinction acquisition and extinction consolidation. The decrement in
the fear response during’extinction training’ is also termed ‘within-
session extinction’. Similar to fearmemory, stabilization of the extinction
memory requires both a cascade of overlapping, but dissociable, molec-
ular and cellular events [for review see (Myers & Davis, 2007; Orsini &
Maren, 2012)] that alter synaptic efﬁcacy and brain systems-level inter-
actions (Pape & Pare, 2010). The strength of extinction memory can be
assessed at some interval (usually N1 day) after extinction training in
“extinction retrieval” sessions (also termed ‘extinction retention’ or ‘ex-
tinction expression’, but note that we use the term “extinction retrieval”
throughout this review).
That extinction memories are prone to re-emergence (due to insuf-
ﬁcient ‘longterm extinction’) indicates that the original fear memory isstill in place and the extinction memory is weaker/more labile than
the fear memory. This may be particularly true of older (‘remote’) fear
memories (Tsai & Graff, 2014). The re-emergence of extinguished fear
occurs under multiple circumstances: (i) renewal, when the CS is
presented in a different context to that in which extinction training
occurred; (ii) reinstatement, when the original US or another stress-
or is given unexpectedly; and (iii) spontaneous recovery, when a sig-
niﬁcant period of time has elapsed following successful extinction
training (Herry et al., 2010; Myers & Davis, 2007). The likelihood of
fear re-emergence is dependent on the strength of the extinction
memory which is also determined by the type of extinction protocol
used see e.g. (Laborda & Miller, 2013; Li & Westbrook, 2008). Spon-
taneous recovery (Rowe & Craske, 1998a,b; Schiller et al., 2008), re-
instatement (Schiller et al., 2008) and renewal (Effting & Kindt,
2007) are all observable in clinical settings, and can be readily
exploited in the laboratory to identify drugs and other interventions
that can prevent fear re-emergence in animals and relapse in
humans (Vervliet et al., 2013).
Box 1
Why pharmacological augmentation of extinction?
A limitation of extinction-based exposure therapy is that patients can often
relapse with the passage of time, with changes in context (out of the therapy
context), or under conditions of stress or other provocations, such as experiencing
trauma reminders. In the parlance of learning theory, extinction memories are
labile and fragile. A key goal for pharmacotherapy, therefore, is to identify
compounds that overcome this fragility, by bolstering the formation, persistence
and possibly context independence of extinction memories. One approach to
achieving this goal is to use drugs as adjuncts to exposure therapy (cognitive
enhancers) as a way to augment the extinction learning process. In this review, we
discuss the various neurochemical and molecular signaling pathways that have
been targeted to this end. On the one hand, there remain signiﬁcant challenges to
overcome, including the selective targeting of extinction-related processes
without concurrent effects on original fear memories. On the other hand, there are
clearly a plethora of potentially promising avenues to pursue, and we are
optimistic that real advances can be made in treating trauma-related disorders.
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of preclinical work on the possible pharmacological approaches (see
Box 1 for an overview) to augment fear extinction and protect against
the re-emergence of fear, and to discuss the potential translational
value of these candidates as adjuncts to exposure-based CBT in anxiety
patients.
2. Neuronal substrates of fear extinction
Using a number of complementary techniques (including electro-
physiology, immediate-early gene mapping, tracing studies, lesioning/
inactivation approaches and optogenetics) research is revealing the
complex and interconnected brain circuitry mediating fear extinction.
Several key brain areas including the amygdala (AMY), hippocampus
(HPC), medial prefrontal cortex (mPFC), periaqueductal gray (PAG),
bed nucleus of the stria terminalis and others have been implicated in
extinction [for recent detailed reviews see (Duvarci & Pare, 2014;
Ehrlich et al., 2009; Herry et al., 2010; Knapska et al., 2012; Myers &
Davis, 2007; Orsini & Maren, 2012; Pape & Pare, 2010)]. Of these, we
focus on the AMY, HPC and mPFC as major, well-deﬁned components
of the fear circuitry (see Fig. 2).
While theAMYand themPFC are crucial for the formation andmain-
tenance of fear extinctionmemories, the HPC, linkedwith themPFC and
the AMY (Pape & Pare, 2010), processes contextual information linked
with extinction (Orsini & Maren, 2012). Altering these hippocampalFig. 2.Anatomy of fear extinction and expression. Fear extinction and expression rely on neuron
gic and GABAergic neurons, among others, are important components of connectivity and regu
While fear neurons in the BA send excitatory projections directly to the centromedial AMY (Ce
cortex (IL) inhibits CeM output by driving inhibitory ITC neurons. IL inputs might also synapse
within the central AMY (CeA) through several routes, possibly by driving inhibitory ITC or CeL (
ultimate inhibition of the CeM. The hippocampus is involved in contextual aspects of extinction
memories built following extinction are encoded by theAMY and themPFC and aremodulated b
changes in synaptic plasticity and interneuronal communication in this circuitry ultimately redu
refered to recent reviews of (Duvarci & Pare, 2014; Orsini & Maren, 2012).contributions to extinction memory or mimicking the hippocampal re-
sponse within the extinction context (see below) may be mechanisms
that render extinction context-independent. The AMY is a core hub in
fear extinction processing. Data in rodents and humans suggest
sustained AMY activity in extinction-impaired individuals, possibly
resulting from a failure to engage pro-extinction circuits in cortical
areas and subregions of the AMY [reviewed in (Holmes & Singewald,
2013)]. Different AMY subregions andneuronal populationshave differ-
ential contributions to extinction. The centromedial AMY (CeM) is the
major output station of the AMY that drives fear via its connections to
the hypothalamus and brainstem regions (Fendt & Fanselow, 1999;
LeDoux et al., 1988; Maren, 2001), and its responding is modulated fol-
lowing extinction via intra-amygdala and remote inputs. Extinction
training has been shown to cause a rapid reduction of CS-evoked re-
sponses of lateral AMY (LA) neurons possibly via depotentiation of tha-
lamic inputs (Duvarci & Pare, 2014). The basal AMY (BA) contains
extinction-encoding neurons which drive GABAergic cells in themedial
intercalated cell masses (ITC) and neurons in the centrolateral AMY
(CeL) to inhibit the CeM and the expression of fear (Duvarci & Pare,
2014; Herry et al., 2008). Following from these initialﬁndings, addition-
al studies involving optogenetic approaches, have shown that a subpop-
ulation of the BA pyramidal neurons which express the Thy1 gene may
mark the extinction neuron subpopulation (Jasnow et al., 2013).
It is also becoming apparent that different ITCs are part of a
GABAergic feed-forward relay station interconnecting AMY nuclei
with distinct networks within the ITCs that are engaged in particular
fear stages exerting different inﬂuences on extinction (Busti et al.,
2011; Duvarci & Pare, 2014; Whittle et al., 2010). Separate neuronal
populations in the CeL have been found to have contrasting roles
in fear and fear extinction. CeL-OFF neurons (PKCδ+ phenotype)
inhibit fear-promoting CeM neurons, while CeL-ON (PKCδ− phenotype)
cells stimulate fear-promoting CeM neurons (Ciocchi et al., 2010;
Haubensak et al., 2010). Additionally, a very recent ﬁnding suggests that
a subpopulation of neurons within the CeM – that of the Tac2 peptide-
expressing cells – is critically involved in fear learning and fear expression
(Andero et al., 2014).
Another important node within the extinction circuitry is the mPFC,
which shares strong interconnections with the HPC and the AMY. Fear
extinction recruits the ventral segment of the mPFC, the infralimbic
(IL) subdivision [the rodent correlate of the human ventromedial PFC
(vmPFC)] which projects to BA extinction and ITC neurons and can
thereby inhibit the activity of CeM fear output neurons [reviewed inal processing in an anatomical circuitry centering on theAMY,mPFC, andHPC. Glutamater-
lation of fear. The AMY is critically involved in the expression of aversive (fear) memories.
M) driving expression of fear (right panel), during extinction (left panel), the infralimbic
directly on “extinction” neurons within the BA. “Extinction” neurons can inﬂuence activity
off, PKC+) neurons that limit CeM activity. There is also a BA–CeL pathway contributing to
via its projections to both the IL and the BA, among other brain regions. Hence, inhibitory
y theHPC. It is thought that extinction training and exposure therapy produce long-lasting
cing fear responses via output stations including the CeM. For further details, the reader is
154 N. Singewald et al. / Pharmacology & Therapeutics 149 (2015) 150–190(Amir et al., 2011; Senn et al., 2014)].When a conditioned cue following
extinction is presented in the extinction (therapy) context, the HPC ac-
tivates the IL (an activation which is absent or less in a novel context),
supporting subsequent CeM inhibition (Herry et al., 2010). The IL subdi-
vision is involved in the consolidation of extinctionmemory and synap-
tic plasticity in this region is crucial for successful extinction retrieval
(Mueller & Cahill, 2010). Impaired extinction has been associated with
relatively low activity in IL neurons, and successful extinction with rel-
atively high IL neuronal activity [reviewed in (Holmes & Singewald,
2013)]. The region of the mPFC neighboring the IL [the prelimbic cortex
(PL) in rodents and the dorsal anterior cingulate in humans] plays an
opposite role to the IL in regulating fear and extinction [reviewed in
(Milad &Quirk, 2012)]. The PL interactswith BA fear neurons, augment-
ing output of the basolateral amygdaloid complex (BLA) and hence CeM
activity (Senn et al., 2014).
There is now strong evidence from both animal and human studies
that these various components of the neural circuit underlying extinc-
tion are functionally disturbed in individuals with impaired extinction
(reviewed in (Holmes & Singewald, 2013) and importantly that suc-
cessful extinction in animals (Whittle et al., 2010) and exposure therapy
in humans (Hauner et al., 2012) can correct these abnormalities by trig-
gering a lasting reorganization of this network.
3. Neurochemical and molecular substrates of fear extinction
Research is revealing that the activity of a number of speciﬁc intra-
cellular signaling cascades [reviewed in (Orsini & Maren, 2012)] carry-
ing biological information from the cell surface to the nucleus, is the
key to successful extinction by modulating gene transcription and ulti-
mately promoting synaptic plasticity in extinction-relevant brain re-
gions. The consolidation of extinction memories requires new protein
synthesis initiated by molecular signaling cascades within the AMY,
HPC and mPFC. The extinction-related molecular signaling and gene
expression modulation can differ considerably in these brain areas
(Cestari et al., 2014). Key molecules in the amygdala include calcium
(Ca2+) inﬂux via NMDA-receptors [in an interaction with α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors] and
VGCCs-mediated activation of Ca2+/calmodulin-dependent protein ki-
nase II (CaMKII) and kinases such as Ca2+ /phospholipid-dependent
protein kinase (PKC), and cAMP-dependent protein kinase A (PKA).
Once activated, these kinases merge into a common mitogen-activated
protein kinase (MAPK)/extracellular regulated kinase (ERK) signaling
pathway initiating cAMP response element binding (CREB) phosphory-
lation and transcription of plasticity proteins [reviewed in (Orsini &
Maren, 2012, see Fig. 3 for overview]. Aspects of this intracellular signal-
ing seem to be disrupted in deﬁcient extinction, as exempliﬁed by
the correlation of impaired extinction with reduced ERK activity in
extinction-relevant brain areas (Cannich et al., 2004; Herry et al., 2006;
Ishikawa et al., 2012). Similarly, aberrant expression of memory-
related genes in these areas is correlated with impaired extinction
(Holmes & Singewald, 2013).
To enable selective therapeutic targeting, an important aim in the
extinction ﬁeld is to identify neural mechanisms and intracellular path-
ways in fear extinction that are different from those involved in fear
memory formation. Many of the intracellular mechanisms are similar,
however there are also a number of distinct processes and features in
fear vs fear extinction learning, including differences in protein synthe-
sis dependence, in brain area- and neuronal population-speciﬁc locali-
zation and recruitment of signaling pathways, in time course of
recruitment, in distinct involvement of certain isoforms of key signaling
components (e.g. ERK1 vs ERK2) and resulting gene expression (Cestari
et al., 2014; Guedea et al., 2011; Lattal et al., 2006; Tronson et al., 2012).
While there are examples of the direct targeting of pharmacologically
important components of the aforementioned intracellular signaling,
e.g. the MAPK/ERK pathway (Fischer et al., 2007; Herry et al., 2006; Lu
et al., 2001) to modulate fear extinction, they were mainly targetedindirectly via membrane receptors e.g. (Cannich et al., 2004; Matsuda
et al., 2010) or ion channels (Davis & Bauer, 2012; Ishikawa et al.,
2012). Theseﬁndings have stimulated the hypothesis that boosting spe-
ciﬁc synaptic plasticity mechanisms by pharmacological means may
constitute novel drug targets to promote fear extinction. Indeed, as
outlined below, systemic and brain region speciﬁc drug studies have
identiﬁed a number of promising compounds which augment the be-
havioral and neurobiological effects of fear extinction. The results of
these studies are building a framework upon which novel therapeutic
interventions to facilitate the efﬁcacy of CBT may be rationally devel-
oped and which may ultimately help to enhance symptom remission
and recovery.
4. Pharmacologically enhancing extinction
4.1. Serotonergic system
The serotonin (5-HT) system is positioned to modulate the extinc-
tion circuitry via ascending 5-HT projections arising from midbrain
raphe nuclei that innervate certain brain structures including the AMY
(BLA N LA≫ CeA), the HPC, the mPFC and the bed nucleus of the stria
terminalis [reviewed in (Burghardt & Bauer, 2013)]. The acquisition
and expression of conditioned fear increases 5-HT release in the BLA,
mPFC and dPAG (Kawahara et al., 1993; Yokoyama et al., 2005;
Zanoveli et al., 2009) though possible changes in 5-HT release during ac-
quisition and consolidation of fear extinction have not been reported to
the best of our knowledge.
There are 16 5-HT receptor subtypes classiﬁed into 7 receptor fami-
lies (5-HT1–7) (Fig. 4). All 5-HT receptors, excluding the 5-HT3 family—
amember of a superfamily of ligand-gated ion channels, aremetabotro-
pic, coupled to Gs (5-HT6 and 5-HT7), Gi/0 (5-HT1, 5-HT4 and 5-HT5) or
Gq (5-HT2) proteins.
To date, research has largely focused on the role of 3 of the 5-HT re-
ceptors in fear extinction; namely 5 HT1A, 5-HT2 and 5-HT3 (Table 1,
Fig. 4). Selective activation of 5-HT1A (Saito et al., 2013; Wang et al.,
2013) or 5-HT2A receptors (Catlow et al., 2013; Zhang et al., 2013) en-
hances extinction. This might occur via 5-HT1A and 5-HT2A receptors
expressed in the mPFC and the LA (Chalmers & Watson, 1991;
Cornea-Hebert et al., 1999; Santana et al., 2004). Both of these receptors
regulatemPFC and LA excitability via direct activation of pyramidal cells
and/or GABAergic interneurons (Llado-Pelfort et al., 2012; Rainnie,
1999; Stutzmann & LeDoux, 1999). 5HT2A agonists increase presynaptic
glutamate release (Aghajanian & Marek, 1999) and increase NMDA re-
ceptor sensitivity (Arvanov et al., 1999) and these are mechanisms
well characterized as being important in extinction (see Section 4.4
Glutamatergic system).
The roles in extinction of other 5-HT receptors or other components
of the 5-HT system, such as melatonin ((Huang et al., 2014) have not
been extensively explored. For example, recent work indicating that
the 5-HT7 receptor regulates emotional memories (Eriksson et al.,
2012), has not been followed up with studies on extinction. However,
5-HT3 receptors have been alsoassociated with fear extinction mecha-
nisms (Table 1). While 5-HT3 antagonists have been found to improve
extinction (Park & Williams, 2012), constitutive deletion of 5-HT3 re-
ceptors has the opposite effect, possibly due to developmental changes
in the 5-HT system (Kondo et al., 2014).
Despite the limited knowledge that we have so far regarding speciﬁc
5-HT receptor contributions to extinction, chronic treatment with SSRIs
to enhance 5-HT availability is the ﬁrst-line therapy for many anxiety
disorders. Acute SSRI treatment induces anxiogenic effects, which can
be prevented with 5-HT2C antagonists in rodents and mimicked by 5-
HT2C agonists administered systemically (Bagdy et al., 2001; Salchner
& Singewald, 2006) or locally into the BLA (Campbell & Merchant,
2003). Chronic treatment with some SSRIs (e.g., ﬂuoxetine) but not all
(e.g., citalopram) enhances extinction in rodents (Table 1) [for a recent
review see (Burghardt & Bauer, 2013)], including models of impaired
e.g. BDNF
Calcineurin
Fig. 3.Overview of pharmacological targets and signaling cascades proposed to be important inmediating synaptic plasticity underlying extinction. The formation of extinctionmemories
requires an intricate regulatory network of signal transduction and gene transcription and translation, leading to a complex pattern of intracellular changes and long-term structural
changes. Various pre- and postsynaptic membrane receptors including ionotropic and metabotropic glutamate receptors, cannabinoid receptors, 5-HT, and dopamine receptors have
been shown to be important targets. Main downstream mechanisms include calcium entry through NMDAR and VGCC in concert with AMPA receptors initiating synaptic plasticity via
calcium-dependent protein kinases (e.g. PKA, PKC, PKM and CamKII, phosphatases (e.g. calcineurin) and activation of the ERK/MAPK pathway. Subsequent interaction with transcription
factors, such as CREB and Zif268 within the nucleus results in a wide range of newly synthesized proteins, such as BDNF important for synaptic plasticity including LTP formation. BDNF
activated TrkB receptors further regulate the ERK/MAPK pathway. Finally, epigenetic modiﬁcations are important in translating neurotransmitter/neuromodulator signaling activity gen-
erated at the synapse into activation/repression of the desired genomic response in the cell nucleus. As outlined in the text, boosting these synaptic plasticity mechanisms by pharmaco-
logical means may constitute the establishment of novel drug targets to promote fear extinction.
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Venlafaxine – a combined 5-HT and noradrenaline reuptake inhibitor
with weaker afﬁnity to the noradrenaline transporter (Owens et al.,
1997) – also improves extinction retrieval and protects against fear re-
instatement in rodents (Yang et al., 2012). Chronic ﬂuoxetine treatment
does not strengthen fear conditioning or fear expression (Camp et al.,
2012) suggesting relative selectivity for extinction. Another clinically
relevant attribute of chronic ﬂuoxetine treatment is the protection it
provides against the return of fear, as assayed by spontaneous recovery
or fear renewal (Deschaux et al., 2011; Deschaux et al., 2013; Karpova
et al., 2011). Furthermore, an important molecular mechanism through
which ﬂuoxetine produces extinction-associated reductions in fearmaybe the transformation of adult plasticity mechanisms to a juvenile state
(Karpova et al., 2011).
These encouraging preclinical discoveries will hopefully stimulate
comprehensive clinical assessment of the efﬁcacy of SSRIs in augment-
ing CBT in anxiety patients (Table 1A). There have been small-scale
clinical trials showing, for example, that paroxetine augments fear re-
ductions (assessed using CAPS scores) and is associated with higher re-
mission rates when combined with CBT in PTSD patients as compared
with a placebo/CBT group. An optional treatment maintenance for an
additional 12 weeks revealed that symptomatic improvements were
long-lasting and consistent although no further improvements could
be detected. However, this may have been due to enhanced drop-out
Fig. 4. Overview of research on the role of the serotonergic system in extinction.
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et al., 2012). More evidence is available in panic disorder (Table 1).
There is evidence that chronic SSRI treatment (ﬂuvoxamine, paroxetine)
increases CBT-induced fear reductions in panic disorder patients
(de Beurs et al., 1995; Oehrberg et al., 1995). However results
concerning the extinction-augmenting ability of SSRIs are not consistent
as SSRIs, including ﬂuvoxamine, ﬂuoxetine, sertraline and paroxetine,
have failed to demonstrate efﬁcacy in primary outcomes [clinical global
impression; (Blomhoff et al., 2001; Davidson et al., 2004; Haug et al.,
2003; Koszycki et al., 2011; Stein et al., 2000). Despite their common ef-
fect of serotonin transporter inhibition, SSRIs are known to differ with
regard to their pharmacological properties. Along these lines, some
SSRIs (e.g. paroxetine) show additional noradrenaline transporter-
inhibiting properties via their metabolites (Owens et al., 1997), while
others (e.g. citalopram) show continued selectivity for the serotonergic
system (Deupree et al., 2007). In this respect, differential effect sizes of
SSRIs are to be expected.
Nevertheless, a number of outstanding questions remain, including
that concerning the speciﬁcity of SSRIs in augmenting fear extinction
as opposed to fear learning (as observed with ﬂuoxetine in preclinical
models; see above). In this respect, the ﬁnding that prior fear condition-
ing administration of escitalopram augments extinction learning in
healthy volunteers without inﬂuencing fear acquisition (Bui et al.,2013) may hint at a potential selectivity of SSRIs to preferentially en-
gage extinction mechanisms. However, this remains to be tested.
In summary, the clinical studies performed so far have demonstrated
that SSRI augmented psychotherapy holds some beneﬁts for panic disor-
der patients and possibly for PTSD and SAD patients. However, further
studies of different SSRIs in larger patient cohorts will be needed, as
well as adequate follow-up time to reveal long-term effects, before
more deﬁnite conclusions can be drawn. Until such studies, as well as
studies investigating receptor selective approaches are available, it
seems rational to recommend combined treatment involving exposure-
based psychotherapy together with antidepressants including SSRIs
such as ﬂuoxetine, as there is more evidence supporting than disproving
such a strategy at the moment.
4.2. Dopaminergic system
An increasing amount of evidence suggests that dopamine (DA)
signaling has an important role in extinction mechanisms (Fig. 5)
[for a recent detailed review, see (Abraham et al., 2014)]. The DAergic
system innervates forebrain extinction circuits through ascending
mesocortical/limbic DAergic projections from the ventral tegmental
area targeting certain brain regions including the mPFC, HPC and AMY
(Pinard et al., 2008; Pinto & Sesack, 2008; Weiner et al., 1991). There
Table 1
Serotonergic signaling in fear extinction (preclinical studies).
Drug/manipulation Extinction training Extinction retrieval Longterm extinction Route Reference
Facilitating 5-HT signaling
SERT KO6 ns – ns No drug (Hartley et al. 2012)
No effect – ns No drug (Wellman et al. 2007)
Acute ﬂuoxetine (SSRI) (−)## No effect ns ip (Lebron-Milad et al. 2013)
Subchronic citalopram (SSRI, 9d) No effect ns ns ip (Burghardt et al. 2013)
Chronic citalopram (SSRI, 22d) – (−) ns ip (Burghardt et al. 2013)
Chronic (14d) ﬂuoxetine (SSRI) (+)# (+) ns po (Lebron-Milad et al. 2013)
Chronic ﬂuoxetine (SSRI) No effect + + (Ren-A, SR, Re-in) ip (Karpova et al. 2011)
No effect ns + (Re-in) ip,po (Deschaux et al. 2011, 2013)
No effect* +*4 ns po (Camp et al. 2012)
No effect + ns po (Popova et al. 2014)
Acute venlafaxine (SSRI) No effect + ns ip (Yang et al. 2012)
Chronic venlafaxine (SSRI) ns ns + (Re-in) ip (Yang et al. 2012)
8-OH-DPAT (5HT1 ag) +*5 (−)*5 ns ip (Wang et al. 2013)
Tandospirone (5HT1 ag) ns +* ns ip (Saito et al. 2013)
tcb2 (5HT2A ag) + ns ns ip (Zhang et al. 2013)
Psilocybin (5HT2A ag) (+) ns ns ip (Catlow et al. 2013)
5-HT3 OE No effect ns ns No drug Harrell and Allan (2003)
Inhibiting 5-HT signaling
5,7-Dihydroxytryptamine (+)# + ns BLA (Izumi et al. 2012)
5,7-Dihydroxytryptamine No effect No effect ns IL (Izumi et al. 2012)
5HT3 KO ns – ns No drug (Kondo et al. 2014)
MDL11,939 (5HT2A ant) – ns ns ip (Zhang et al. 2013)
Ketanserin (5HT2A/C ant) (+) ns ns ip (Catlow et al. 2013)
Granisetron (5HT3 ant) No effect (+) ns ip Park and Williams (2012)
1drug administration following extinction training; 2 SERT-KO results in increased synaptic 5-HT levels; 3 7 days; 4 protection from context over-generalization; 5 valproate-inducedmodel
of autism, 6 SERT-KO results in increased synaptic 5-HT levels.
* facilitates rescue of impaired fear extinction; # reduced fear expression at the beginning of extinction training; ## enhanced fear expression at the beginning of extinction training.
+, improved;−, impaired; (+) or (−), only minor effects; po, peroral administration; ip, intraperitoneal injection; ns, not studied; BLA, intra-basolateral amygdala administration; IL,
infralimbic cortex; Ren-A, Fear renewal in conditioning context; SR, spontaneous recovery; Re-in, reinstatement; ag, agonist; ant, antagonist, KO, knock-out; OE, over-expression.
In “Extinction training” (or ‘within-session extinction’), an effect on the reduction of the behavioral response (e.g. freezing) in response to repeated CS presentations is described.
In “Extinction retrieval”, an effect on the recall of the extinction memory 24h following extinction training is described.
In “Long-term extinction” an effect on the robustness of the extinctionmemory in terms of protection against spontaneous recovery of fear (passage of time), fear renewal (re-exposure to
conditioning context or a novel context which is distinct to the conditioning and extinction context) and fear reinstatement (US re-exposure) is described.
In this reviewwe aimed to summarize (druggable) systems involved in fear extinction and how pharmacological compounds have been utilized to augment fear extinction in preclinical
(rodent) and small-scale clinical studies.Wedid not differentiate betweendata gained fromeithermice or rats as thiswould havegonebeyond the scope of this review. However, excellent
species differentiation has been provided by others (e.g. (Makkar et al. 2010,Myers et al. 2011, Bowers et al. 2012, Riaza Bermudo-Soriano et al. 2012, Burghardt and Bauer 2013, Fitzgerald
et al. 2014a).
157N. Singewald et al. / Pharmacology & Therapeutics 149 (2015) 150–190is increased dopamine release in themPFC during and following extinc-
tion training (Hugues et al., 2007) and boosting DAergic signaling with
DA precursors or DA-releasing drugs facilitates extinction consolidation
(Abraham et al., 2012; Haaker et al., 2013) and can rescue impaired fear
extinction in female rats (Rey et al., 2014). Conversely, reducing
DAergic transmission by lesioning mesocortical DAergic projection
neurons (with 6-OH-DOPA) impairs extinction memory formation
(Fernandez Espejo, 2003; Morrow et al., 1999) (see summary in
Table 2). More recently, there have been further insights into themech-
anisms of how and where DAergic signaling can inﬂuence fear extinc-
tion have been made. These studies (see Table 2 and below) have
revealed a complex two-pronged feature of DAergic signaling that can
(i) gate the expression of fear, and (ii) inﬂuence fear extinction consol-
idation mechanisms.
Dopamine receptors are metabotropic and in the classical view,
coupled to either Gs (increased cAMP, D1-like) or Gi/0 (decreased
cAMP, D2-like) proteins. However, DAergic signals can also be trans-
duced via Phospholipase C (PLC) activation (enhanced DAG, IP3) medi-
ated by D1-like Gα proteins, by D2-like Gβγ subunits or by receptors
forming D1/D2 heteromers (Felder et al., 1989; Lee et al., 2004) [for re-
view see (Abraham et al., 2014)]. The D1-class receptor signaling mod-
ulates the excitability of BLA parvalbumin-positive interneurons
(Bissiere et al., 2003; Kroner et al., 2005; Loretan et al., 2004) and ITCs
(Manko et al., 2011). In concert with D2-like receptors in the CeL/CeC
(Perez de la Mora et al., 2012), DAergic signaling exerts tight control
over CeM-mediated expression of fear. To date, however, pharmacolog-
ical manipulation of DAergic signaling in the AMY has producedconﬂicting results with regard to extinction (Fiorenza et al., 2012;
Hikind & Maroun, 2008) (see Table 2).
Preclinical work has aimed to clarify the role of DA receptor ac-
tivity in extinction. However, research has been largely complicated
by the lack of receptor subtype-selective compounds, leaving many
investigations reliant on drugs acting on D1-like (D1, D5) and D2-
like (D2, D3, D4) receptor subfamilies. One reliable ﬁnding, howev-
er, is that DA antagonism (see Table 2) speciﬁcally in the mPFC im-
pairs the retrieval of extinction memories (Hikind & Maroun,
2008; Mueller et al., 2010; Pfeiffer & Fendt, 2006). In this case,
DAergic effects on glutamatergic NMDA receptor signaling may be
involved. As discussed below (Section 4.4 Glutamatergic system),
NMDA receptor-mediated burst activity of mPFC neurons is associ-
ated with stabilization of extinction memories (Burgos-Robles
et al., 2007) and D1-like receptor agonists facilitate NMDA receptor
currents via Gsmediated increases in adenylate cyclase (AC) activity
(Snyder et al., 1998). There is also the possibility that D2 receptor
mechanisms in the PFC support extinction, as (Mueller et al., 2010)
showed that a pre-extinction IL injection of the D2 antagonist
raclopride impaired the consolidation of extinction memory. How-
ever, following systemic administration of the (less selective) D2
receptor antagonist sulpiride, accelerated extinction was found
(Ponnusamy et al., 2005).
In summary, the results of preclinical studies do not yet fully clarify
the speciﬁc DA receptor or receptor class mediating the extinction aug-
menting effect of enhanced dopaminergic signaling. Work still needs to
be done on the use of receptor-selective agonists and antagonists, as
Table 1A
Human trials: serotonergic drugs combined with CBT.
Disorder Study design Outcome (compared to placebo control group) Reference
Healthy volunteers 14 days po escitalopram pretreatment; fear
conditioning paradigm
Accelerated extinction learning (skin conductance responses) (Bui et al., 2013)
Panic disorder with/without
agoraphobia
Fluvoxamine or placebo followed by exposure
therapy; psychological panic management followed
by exposure therapy or exposure therapy alone
Self-reported measures
All treatments effective, however ﬂuvoxamine plus CBT
superior to all other treatments
(de Beurs et al., 1995)
Panic disorder with/without
agoraphobia
12 weeks paroxetine or placebo plus CBT Reduced number of panic attacks in paroxetine/CBT group (Oehrberg et al., 1995)
Panic disorder with/without
agoraphobia
10 weeks of paroxetine or placebo plus CBT in week 5
and 7
No signiﬁcant difference in primary CGI outcome.
Secondary outcome: Higher proportion of panic-free
patients in paroxetine-CBT group.
(Stein et al., 2000)
Panic disorder with/without
agoraphobia
12 weeks ﬂuvoxamine or placebo with or without
CBT
All groups except placebo without CBT improved.
No difference within other groups.
(Sharp et al., 1997)
Panic disorder with/without
agoraphobia
12 weeks of sertraline or placebo treatment plus
self-administered CBT or no CBT
Reduced anticipatory anxiety in sertraline plus
self-administered CBT
No signiﬁcant improvements in CGI.
(Koszycki et al., 2011)
Social anxiety disorder 24 weeks of sertraline/placebo with or without
exposure therapy (8 sessions in the ﬁrst 12 weeks of
treatment)
All groups improved (also placebo without CBT)
Sertraline treatment (without CBT) showed higher
improvement than CBT groups (placebo or sertraline).
Placebo without CBT showed lowest beneﬁts.
(Blomhoff et al., 2001)
Social anxiety disorder Follow-up study of (Blomhoff et al., 2001)
Assessment of long-term effects 28 weeks after
cessation of medical treatment
Exposure therapy alone (without placebo or sertraline)
showed a further improvement in CAPS 28 weeks after
treatment cessation, however only reached improvement
levels comparable with those of the sertraline alone group
after the initial 24 weeks
CAPS score in the other groups (Exposure + placebo or
sertraline and placebo alone) stayed constant (no
improvement compared to 24 week CAPS score)
(Haug et al., 2003)
Social anxiety disorder 14 weeks of ﬂuoxetine or placebo plus weekly CBT or
no CBT
CBT consisted of group treatment combining in vivo
exposure, cognitive restructuring and social skills
training
All treatments were superior to placebo (without CBT) but
no differences between groups themselves
(Davidson et al., 2004)
PTSD 10 exposure therapy sessions
(1×/week) plus paroxetine CR
Optional 12 weeks of maintenance treatment
Greater CAPS improvement in paroxetine group vs
placebo after 10 weeks
Higher rate of remission (61.5% vs 23.1% in placebo group)
after 10 weeks
No changes after additional 12 weeks. CAVE drop-out of
remitters.
(Schneier et al., 2012)
CR…controlled release.
158 N. Singewald et al. / Pharmacology & Therapeutics 149 (2015) 150–190well as biased ligands (showing functional selectivity for either AC
or PLC signal transduction pathways) to reveal receptor-speciﬁc
functions and theirmodulation of downstream signaling cascades in ex-
tinction. Pharmacologically increasing the DA tone promotes extinction.
L-DOPA administration following extinction training enhances fear ex-
tinction in mice and healthy humans, rendering extinction resistant to
fear renewal, reinstatement and spontaneous recovery (Haaker et al.,
2013). L-DOPA is a precursor for all catecholamines, but preferentially
enhances dopaminergic turnover in the frontal cortex (Dayan &
Finberg, 2003), eliciting D1- and D2-like receptor responses (Trugman
et al., 1991). Indeed, L-DOPA augments extinction-related neural activ-
ity in the mPFC (IL) of mice and increases mPFC functional coupling
in humans (Haaker et al., 2013). These ﬁndings have immediate transla-
tional potential because L-DOPA is a US Food and Drug Administration-
approved compound used in the treatment of Parkinson's disease,
typically in combination with carbidopa (a peripheral decarboxylase
inhibitor) to maximize central availability and minimize peripheral
side effects. While there are abuse related issues with any DA en-
hancer, this could be mitigated by supervised, acute treatment dur-
ing CBT. Encouragingly, a small-scale clinical trial found improved
efﬁcacy of psychotherapy in treatment-resilient PTSD patients by ad-
ministration of another DA-enhancing drug, MDMA (Mithoefer et al.,
2011) and a follow-up indicated robust fear reductions for up to 74
months [(Mithoefer et al., 2013), see Table 2A]. A caveat here is
that it is unclear whether these effects of MDMA are solely attribut-
able to its effects on DA, and not also to its effect on other targets of
MDMA, notably 5-HT. Nonetheless, boosting DA transmission inconjunction with CBT could have signiﬁcant potential translational
value.
4.3. Noradrenergic system
The noradrenergic system is crucial for both the formation and the
maintenance of fear memories, as well as for extinction memories
(reviewed in (Holmes & Quirk, 2010; Mueller & Cahill, 2010)).
Noradrenaline can enhance neuronal excitability in extinction-
relevant brain regions such as the IL (Mueller et al., 2008) and successful
fear extinction is associated with enhanced extracellular levels of nor-
adrenaline in the mPFC (Hugues et al., 2007). Boosting noradrenaline
levels, via administration of either noradrenaline itself (Merlo &
Izquierdo, 1967) or of compounds such as yohimbine (see below) or
methylphenidate (Abraham et al., 2012) enhances fear extinction
(Table 3). There is evidence from preclinical studies that activating
β-adrenoceptors, one target receptor of noradrenaline, can also facili-
tate fear extinction (Table 3) [for recent review, see (Fitzgerald et al.,
2014a)]. Conversely, depleting central noradrenaline or lesioning as-
cending noradrenaline projections from the locus coeruleus, impairs ex-
tinction, as does systemic alpha1 or β adrenoceptor blockade (Table 3)
[reviewed in (Mueller & Cahill, 2010)].
There has been interest in the clinical utility of targeting noradrenergic
mechanisms to augment extinction. Here, we focus onα2-adrenoceptors
given the recent clinical ﬁndings supporting the utility of α2-
adrenoceptor antagonists in improving extinction. Based on results of
rodent studies (Cain et al., 2004), two small clinical studies (Powers
Fig. 5. Overview of research on the role of the dopaminergic system in extinction.
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with CBT can reduce anxiety in patients with social anxiety disorder
and claustrophobic fear (Table 3A). A third study found no CBT-
augmenting beneﬁt of yohimbine in patientswith fear of ﬂying; howev-
er, CBTmay have exerted a ‘ceiling effect’ that occluded the drug's effect
(Meyerbroeker et al., 2012).
In rodents, blocking α2-adrenoceptors (e.g., with yohimbine) that
function as autoreceptors on locus coeruleus neurons increases locus
coeruleus activity and noradrenaline release in terminal regions
(Singewald & Philippu, 1998). Yohimbine is anxiogenic and increases
neuronal activity in widespread brain areas, including extinction-
relevant areas such as the amygdala, mPFC and HPC (Singewald et al.,
2003). Downstream targets of yohimbine-induced noradrenaline release
include β1-adrenoceptors, and increasing activity at these receptors
in locus coeruleus terminal regions (mPFC) enhances extinction
(Do-Monte et al., 2010b), possibly via facilitating extinction-relevant
long-term potentiation (Gelinas & Nguyen, 2005) in a BDNF-
dependentmanner (Furini et al., 2010). Yohimbine facilitates extinction
in rodents, including extinction-impaired subjects (Hefner et al., 2008,2008), though a more selective α2-adrenoceptor, atipamezole, does
not (Table 3) [for further discussion, see (Holmes & Quirk, 2010)].
Yohimbine also protects against spontaneous fear recovery, in amanner
similar to the effect of a noradrenaline uptake inhibitor, atomoxetine
(Janak & Corbit, 2011). However, yohimbine reduces fear only in the ex-
tinction context in which the drug was administered (Morris & Bouton,
2007), which would be a limitation of the clinical goal of achieving
context-independent reductions in fear. Thus, other strategies may be
needed, including combination strategies where drugs which do pro-
duce context-independent extinction, for example targeting HDACs
(see Section 4.10 Epigenetics), are combined with yohimbine.
4.4. Glutamatergic system
Glutamatergic signaling plays a crucial role in synaptic plasticity
and many forms of learning and memory, including fear extinction
(see Fig. 6 for an overview). Fast excitatory glutamatergic signaling is
mediated by ionotropic receptors (NMDA and AMPA), and slower sig-
naling by metabotropic (mGluR1–8) receptors. Group I (mGluR1 and
Table 2
Dopaminergic signaling in fear extinction (preclinical studies).
Drug/manipulation Extinction training Extinction retrieval Longterm extinction Route Reference
Facilitating DA signaling
L-DOPA ns +1 + (SR, Re-in2, Ren-A ip (Haaker et al., 2013)
Amphetamine − ns ns ip (Borowski and Kokkinidis, 1998)
No effect ns ns ip (Carmack et al., 2010)
(+)3 (−) ns ip (Mueller et al., 2009)
Cocaine − ns ns ip (Borowski and Kokkinidis, 1998)
Methyl-phenidate + (+) ns ip (Abraham et al., 2012)
ns +1 ns ip (Abraham et al., 2012)
SKF38393 (pAg D1) − ns ns ip (Borowski and Kokkinidis, 1998)
+*4 ns ns ip (Dubrovina and Zinov'eva, 2010)
ns +1 ns CA1 (Fiorenza et al., 2012)
ns No effect1 ns BLA (Fiorenza et al., 2012)
ns No effect1 ns IL (Fiorenza et al., 2012)
ns +6 ns ip (Rey et al., 2014)
ns −7 ns ip (Rey et al., 2014)
Quinpirole (D2 ag) ns − ns ip (Ponnusamy et al., 2005)
ns − ns ip (Nader and LeDoux, 1999)
−4 ns ns ip (Dubrovina and Zinov'eva, 2010)
Inhibiting DA signaling
6-OH DOPA − ns ns mPFC (Morrow et al., 1999)
− (−) ns mPFC (Fernandez Espejo, 2003)
D1 knock-out − ns ns global KO (El-Ghundi et al., 2001)
SCH23390 (D1 ant) ns No effect1 ns IL (Fiorenza et al., 2012)
− No effect ns BLA (Hikind and Maroun, 2008)
No effect − ns IL (Hikind and Maroun, 2008)
ns −1 ns CA1 (Fiorenza et al., 2012)
ns No effect1 ns BLA (Fiorenza et al., 2012)
Sulpiride (D2 ant) − ns ns ip (Dubrovina and Zinov'eva, 2010)
ns + ns ip (Ponnusamy et al., 2005)
No effect No effect ns ip (Mueller et al., 2010)
Raclopride (D2 ant) (−) No effect ns ip (Mueller et al., 2010)
No effect − ns IL (Mueller et al., 2010)
Haloperidol (D2/D3 ant) − ns ns ip (Holtzman-Assif et al., 2010)
(−) ns ns icv (Holtzman-Assif et al., 2010)
(−) − ns NAcb (Holtzman-Assif et al., 2010)
L-741,741 (D4 ant) No effect − ns mPFC (Pfeiffer and Fendt, 2006)
1 Drug administration following extinction training, 2 37 days, 3 increased locomotion, 4 passive avoidance paradigm, 5 reduced locomotion with 0.3 mg/kg, no effect on locomotion,
extinction training and retrieval with 0.1 mg/kg, 6 rescued impaired extinction retrieval in estrus/metestrus/diestrus, 7 impairs extinction retrieval in proestrus.
* Facilitates rescue of impaired fear extinction; # reduced fear expression at the beginning of extinction training; ## enhanced fear expression at the beginning of extinction training.
+, Improved;−, impaired; (+) or (−), only minor effects; ip, intraperitoneal injection; ns, not studied; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; mPFC,
medial prefrontal cortex; CA1, cornu ammonis 1; NAcb, nucleus accumbens; Ren-A, Fear renewal in conditioning context; SR, spontaneous recovery; Re-in, reinstatement; ag, agonist;
ant, antagonist, KO, knock-out;
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to Gq proteins enhancing phospholipase C (PLC) activity. Group II
(mGluR2, mGluR3) and Group III (mGluR4, mGluR6–mGluR8) are
both coupled to Gi proteins inhibiting adenylate cyclase (AC) activity
and expressed on pre- as well as postsynaptic sites (Willard &
Koochekpour, 2013).
Pharmacological potentiation of AMPA receptor activation (by
PEPA) facilitates extinction learning and retrieval (Yamada et al., 2009,
2011; Zushida et al., 2007), although it is ineffective in severely
extinction-impaired subjects (Whittle et al., 2013). Studies using local-
ized infusion of AMPA potentiators (Zushida et al., 2007) and blockers
(Falls et al., 1992; Milton et al., 2013; Zimmerman & Maren, 2010)
coupled with electrophysiological recordings suggest that AMPA-
mediated effects on extinction are localized to the mPFC [(Zushida
et al., 2007) see Table 4, for recent detailed reviews (Bukalo et al.,
2014; Myers et al., 2011)].
The part played in extinction by themetabotropic glutamate receptors
mGluR1, mGluR5 and mGluR7 has also been evaluated. Antagonizing
mGluR1 (which is expressed on ITC innervating neurons (Busti et al.,
2011) with CPCCOEt (Kim et al., 2007) and antagonizing mGluR5 recep-
tors in the IL (Sepulveda-Orengo et al., 2013) have been shown to impair
extinction. Furthermore, gene mutations resulting in deﬁcits in mGluR5
(Xu et al., 2009) or mGluR7 (Callaerts-Vegh et al., 2006; Fendt et al.,
2008; Goddyn et al., 2008) impair extinction learning, while selective ac-
tivation (Dobi et al., 2013; Fendt et al., 2008; Morawska & Fendt, 2012;
Rodrigues et al., 2002; Siegl et al., 2008; Toth et al., 2012b; Whittle et al.,2013) improves extinction [see Table 4 for summary and (Bukalo et al.,
2014; Myers et al., 2011) for more details].
The most extensively studied glutamate receptor in relation to fear
extinction is the NMDA receptor (NMDAR). As shown in Table 4,
systemic or local administration of NMDAR antagonists into the BLA or
mPFC produces extinction deﬁcits [reviewed in (Myers et al., 2011)].
Due to the potential for major side-effects (e.g. excitotoxicity) a general
enhancement of NMDAR transmission is clinically undesirable and
more subtle modulation of NMDAR signaling is required. NMDARs are
specialized voltage-dependent, ligand-gated ion channels that are
expressed as heterotetramers formed by GluN1 in combination with
GluN2 or GluN3 subunits. To date, eight different splice variants of the
GluN1 subunit, four distinctive GluN2 (GluN2A–D) subunits and two
GluN3 (GluN3A–B) subunits have been identiﬁed [for review see
(Paoletti et al., 2013)]. Activation of NMDARs requires L-glutamate
binding to GluNR2 subunits, L-glycine or D-serine binding to GluNR1
subunits and membrane depolarization relocating the channel pore-
blocking Mg2+ and Zn2+ ions.
The repertoire of NMDAR subunits permits the assembly of a
range of NMDARs with varying dissociable signaling properties.
Systemic (Dalton et al., 2008; Dalton et al., 2012; Leaderbrand et al.,
2014; Sotres-Bayon et al., 2007) or localized BLA (Laurent &
Westbrook, 2008; Sotres-Bayon et al., 2007; Sotres-Bayon et al., 2009)
or mPFC (Laurent & Westbrook, 2008; Sotres-Bayon et al., 2009)
inhibition of GluN2B-containing NMDARs (via ifenprodil or Ro25-
6981) disrupts extinction. Conversely, GluN2B overexpression
Table 2A
Human trials: dopaminergic enhancers combined with CBT.
Disorder Study design Outcome (compared to placebo control group) Reference
Healthy volunteers Fear conditioning paradigm, L-DOPA po following
extinction training
Protection from renewal (skin conductance responses) (Haaker et al., 2013)
PTSD (treatment-refractory) 2 single oral MDMA prior to 8h therapy session (3–5 weeks
apart, patients also received therapy prior to ﬁrst MDMA
exposure as well as between and in follow-up)
MDMA augmented CBT in comparison to placebo (83%
vs 25% response)
(2 month follow-up); open-label MDMA use offered to
patients from the placebo group after last assessment
(Mithoefer et al., 2011)
PTSD (treatment-refractory) Follow-up study from (Mithoefer et al. 2011) MDMA augmented CBT produced long-lasting effects
(17–74 months)
(Mithoefer et al., 2013)
161N. Singewald et al. / Pharmacology & Therapeutics 149 (2015) 150–190enhances extinction (Tang et al., 1999). Recently, facilitated signaling
of GluN2C/D-containing NMDARs in the BLA (via CIQ infusion) was
also demonstrated to enhance extinction (Ogden et al., 2014).
The contribution of other subunits, such as GluN2A, remains to be
determined.
The organization ofNMDARsprovides additional druggable pharma-
cological targets. GluN1 and GluN2 subunits are endowed with binding
sites for positive and negative allosteric regulations that enable ﬁne-
tuning of NMDAR activity. The GluN1 subunit contains an inhibitory
H+ binding site rendering GluN2B/D-containing NMDARs in particular
sensitive to local pH changes, as well as to endogenous molecules with
redox potential (Banke et al., 2005). The GluNR2 subunit is responsive
to allosteric modiﬁcation of NMDAR signaling by polyamines such as
spermidine. Spermidine-induced activation of GluN2B signaling facili-
tates the consolidation of extinction (Gomes et al., 2010; Guerra et al.,
2006), while arcaine, an antagonistic polyamine, disrupts extinction
(Gomes et al., 2010). A GluN2 allosteric binding site – still uninvestigated
in the ﬁeld of fear extinction – enables modulation of NMDAR signaling
by neurosteroids (i.a. allopregnanolone) (Irwin et al., 1994).
Nuanced pharmacological modulation of NMDARs can also be
achieved by targeting the Zn2+ binding domain found on GluN2 sub-
units. Zn2+-binding to this modulatory site mainly inhibits GluN2A-
containing NMDARs, by reducing NMDAR channel open probability
(Paoletti et al., 1997). Brain Zn2+ signaling which, in addition to the
NMDAR binding site, acts via other sites including the GPR39 Zn-
sensing receptor (Holst et al., 2007), has been shown to exert both en-
hancing and attenuating effects on learning and memory via complex
interactionswithneurotransmitters and synaptic plasticitymechanisms
(reviewed in Takeda & Tamano, 2014). Dietary Zn2+ supplementation
impairs extinction (Railey et al., 2010), while dietary-induced reduction
of brain Zn2+ levels rescues deﬁcient extinction (Whittle et al., 2010).
Although these effects may be mediated by Zn2+ modulation of
NMDAR signaling, other actions cannot be excluded (e.g., see discussion
on HDAC inhibition in Section 4.10: Epigenetics). The same is true for
another NMDAR-modulating ion, Mg2+, which has also been shown
to facilitate extinction when globally enhanced in the brain (Abumaria
et al., 2011; Mickley et al., 2013).
The most extensively investigated allosteric modulation of NMDARs
is mediated via the L-glycine binding site on the GluN1 subunit. As
shown in Table 4, systemic administration of ligands on this binding
site, D-serine or D-cycloserine (DCS), augments extinction consolidation
[see (Bukalo et al., 2014;Myers et al., 2011) for recent detailed reviews].
There is evidence (although not consistent) that DCSmay promote gen-
eralization of the extinction effect (Ledgerwood et al., 2005; Vervliet,
2008) that is, to other cues (e.g. odors, sounds, visual stimuli) that ac-
quired fear during a more complex conditioning situation. Generalized
extinction could be of potential clinical beneﬁt, provided that cues
that trigger adaptive reactions are not affected. However, DCS adminis-
tration outside the consolidation window can limit the drug's effective-
ness. When extinction or exposure sessions are too short or yield
insufﬁcient fear inhibition, DCS can strengthen (re-)consolidation of
the original fear memory. Along these lines, the extinction augmenting
effects of DCS require the subject to show at least some ability to extin-
guish (Bolkan & Lattal, 2014; Bouton et al., 2008; Hefner et al., 2008;Smits et al., 2013b; Tomilenko & Dubrovina, 2007; Weber et al., 2007;
Whittle et al., 2013). Finally, chronic DCS treatment leads to loss of ef-
fects on extinction, possibly via NMDAR desensitization (Parnas et al.,
2005; Quartermain et al., 1994). It is of note, that chronic treatment
with antidepressants also disrupts the facilitating effects of DCS on ex-
tinction, possibly by interfering with NMDAR function (Werner-
Seidler & Richardson, 2007).
Notwithstanding these caveats, DCS represents one of the best ex-
amples of translational research paving the way for novel anxiety treat-
ments. DCS augmentation of CBT has been clinically studied in various
anxiety disorders (Table 4A) including among pediatric patients [see
(Hofmann et al., 2013a) for a recent review]. To summarize the current
clinical data, DCS-augmented CBT shows advantages in PTSD (de Kleine
et al., 2012; Difede et al., 2014; Scheeringa & Weems, 2014), speciﬁc
phobia (Guastella et al., 2007; Nave et al., 2012; Ressler et al., 2004),
SAD (Guastella et al., 2008; Hofmann et al., 2006; Hofmann et al.,
2013b; Smits et al., 2013c) and OCD [(Chasson et al., 2010; Farrell
et al., 2013; Kushner et al., 2007; Storch et al., 2010; Wilhelm et al.,
2008) but see (Mataix-Cols et al., 2014)]. Panic disorder patients (Otto
et al., 2010c; Siegmund et al., 2011) also show faster symptom allevia-
tion after DCS-augmented CBT. Reﬂecting the preclinical ﬁndings, nega-
tive outcomes were associated with short CBT sessions (Litz et al.,
2012), insufﬁcient within-session fear inhibition (Smits et al., 2013b;
Tart et al., 2013), chronic DCS treatment (Heresco-Levy et al., 2002),
DCS administration outside the therapeutic temporal window (Storch
et al., 2007) and subclinical levels of fear [(Guastella et al., 2007;
Gutner et al., 2012) but see (Kuriyama et al., 2011)].
If these factors are properly attended to [see above, reviewed in
(Hofmann, 2014)], the evidence supports the adjunctive treatment of
CBT with DCS for a range of anxiety disorders.
4.5. γ-Aminobutyric acid (GABA)
GABA is the main inhibitory neurotransmitter in the adult mamma-
lian brain. Because extinction largely reﬂects the promotion of active in-
hibitory processes, it is not surprising that GABA serves as an important
source of such inhibition. GABA signaling occurs largely via binding to
ionotropic GABAA and metabotropic GABAB receptors (former GABAC
receptors have been reclassiﬁed and are now termed GABAA rho-
subclass receptors). GABAA receptors are pentameric, ligand-gated Cl−
channels which, upon activation induce hyperpolarization of cells and
hence reduce neuronal excitability. Seven classes of GABAA subunits
(α1–6, β1–3, γ1–3, ρ1–3, δ, ε, ) have been identiﬁed so far, permitting
the assembly of highly variable GABAA receptors with distinct functions
and signaling properties. Furthermore, several allosteric binding sites, in
addition to the GABA binding pocket located at the α/β-subunit inter-
face, allownuancedmodiﬁcations of GABAA receptor signaling. The allo-
steric benzodiazepine (BZD) binding site is localized at the interface of
α-and γ-subunits and when activated, facilitates GABAergic transmis-
sion by promoting GABA binding to the receptor and increasing the
opening probability of the Cl− channel. The binding sites of other allo-
steric modulators of GABAA signaling including barbiturates and
neurosteroids among others are not yet fully characterized [see Fig. 7
and (Gunn et al., 2014; Makkar et al., 2010)].
Table 3
Noradrenergic (NE) signaling in fear extinction (preclinical studies).
Drug/manipulation Extinction learning Extinction retrieval Longterm extinction Route Reference
Enhancing noradrenergic signaling
Noradrenaline ns + ns icv (Merlo and Izquierdo, 1967)
Methylphenidate + + ns ip (Abraham et al., 2012)
Noradrenaline ns +1 ns BLA (Berlau and McGaugh, 2006)
ns No effect1 ns BLA (Fiorenza et al., 2012)
ns No effect1 ns CA1 (Fiorenza et al., 2012)
ns −1 ns IL (Fiorenza et al., 2012)
Atomoxetine (NE reuptake inhibitor) ns No effect6 + (SR)5 systemic (Janak and Corbit, 2011)
Isoproterenol (β ag) No effect ns ns ip (subchronic) (Do-Monte et al., 2010b)
ns (+)1 ns ip (subchronic) (Do-Monte et al., 2010b)
ns (+)1 ns mPFC (Do-Monte et al., 2010b)
Yohimbine (α2 ant)8 + ns ns sc (Cain et al., 2004)
ns No effect1 ns sc (Cain et al., 2004)
+#2 +2 ns sc (Cain et al., 2004)
+ + − ip (Morris and Bouton, 2007)
No effect7 No effect ns ip (Mueller et al., 2009)
ns +* ns ip (Hefner et al., 2008)
ns No effect6 + (SR)5 systemic (Janak and Corbit, 2011)
Atipamezole (α2 ant)8 ns No effect4 ns sc (Davis et al., 2008)
Inhibiting noradrenergic signaling
Prazosine (α1 ant) ns No effect1 ns ip (subchronic) (Do-Monte et al., 2010a)
− ns ns ip (subchronic) (Do-Monte et al., 2010a)
− ns ns intra-mPFC (Do-Monte et al., 2010a)
Propanolol (β ant) No effect ns ns sc (Cain et al., 2004)
ns No effect1 ns sc (Cain et al., 2004)
No effect2 (−)3 ns sc (Cain et al., 2004)
(+)# No effect ns ip (Rodriguez-Romaguera et al., 2009)
− − ns ip (subchronic) (Do-Monte et al., 2010b)
ns No effect1 ns ip (subchronic) (Do-Monte et al., 2010b)
Atenolol (β ant) − ns ns mPFC (Do-Monte et al., 2010b)
ns No effect1 ns mPFC (Do-Monte et al., 2010b)
Sotalol (β ant) No effect No effect ns ip (Rodriguez-Romaguera et al., 2009)
Timolol (β ant) ns +1 ns BLA (Fiorenza et al., 2012)
Propanolol (β ant) No effect − ns IL (Mueller et al., 2008)
ns No effect1 ns IL (Mueller et al., 2008)
Timolol (β ant) ns +1 ns IL (Fiorenza et al., 2012)
ns No effect1 ns CA1 (Fiorenza et al., 2012)
1 Drug administration following extinction training; 2 spaced CS extinction, US=0.7mA; 3 spaced CS extinctionwhen US=0.4mA; no effect when US=0.7mA, 4 cocaine-conditioned place
preference, 5 4 weeks, 6 instrumental lever press response, 7 reduced fear expression at start of extinction training, if extinction is performed in the same context as conditioning, 8 note that
the net effect of α2 blockade is enhancement of noradrenergic signaling (see text).
* Facilitates rescue of impaired fear extinction; ** facilitates extinction of remotememories, *** only in older animals (7months), younger ones (2months) are not affected, # reduced fear
expression at the beginning of extinction training.
+, Improved;−, impaired; (+) or (−), only minor effects; ip, intraperitoneal injection; injection; sc, subcutanous injection; icv, intracerebroventricular injection; ns, not studied; HPC,
intra-hippocampal administration; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; PL, prelimbic cortex; CA1, cornu ammonis 1; Ren, Fear renewal; SR, spontaneous
recovery; Re-in, reinstatement; ag, agonist; ant, antagonist, KO, knock-out; #, reduced fear expression at start of extinction training.
162 N. Singewald et al. / Pharmacology & Therapeutics 149 (2015) 150–190In preclinical studies, the robust inhibitory effect of full GABAA
receptor agonists at the GABA binding site (α/β-subunit interface)
(e.g. muscimol), is often used to inactivate a brain region to clarify its
participation in certain functions including extinction. Muscimol-
injections into the BLA (Laurent & Westbrook, 2008; Laurent et al.,
2008; Sierra-Mercado et al., 2011), mPFC/IL (Laurent & Westbrook,
2008, 2009; Sierra-Mercado et al., 2011) and HPC [(Corcoran et al.,
2005; Sierra-Mercado et al., 2011), see Table 5 for a summary] disrupt
extinction learning and memory, supporting the crucial involvementTable 3A
Yohimbine combined with CBT in small-scale clinical trials.
Disorder Study design
Social anxiety disorder (SAD) 4 sessions consisting of yohimbine being administered
prior to a CBT a session
Claustrophobic fear 1 single oral yohimbine dose prior to an exposure b session
Fear of ﬂying 2 single oral yohimbine prior to VRET session
VRET, virtual reality exposure.
a CBT involved an oral presentation on challenging topics in front of the therapists, other gr
b behavioral approach task,
c Lack of yohimbine effectmight possibly have beendue to thepowerful inﬂuence of VRET ex
(drug condition) that ‘washed out’ or overrode any effect of manipulation (Meyerbroeker et aof these areas. However, muscimol infusion into the BLA and IL facili-
tates extinction in some studies (Akirav et al., 2006).
There is solid evidence that fear extinction learning is associated
with upregulation of GABAergic markers in the AMY, underscoring the
importance of a certain level of GABAergic signaling in this brain area
for the successful formation of extinctionmemories. For example, levels
of gephyrin, a clustering protein facilitating postsynaptic scaffolding of
GABAA receptors, were enhanced 2 h following extinction training
along with enhanced surface expression of GABAA receptors inOutcome (compared to placebo control group) Reference
Yohimbine augmented CBT-induced improvement in
SAD (self-report measures; 21 day follow-up)
(Smits et al., 2014)
Yohimbine augment CBT-induced reduced fear of
enclosed spaces (7 day follow-up)
(Powers et al., 2009)
No fear augmenting effect of yohimbine c (Meyerbroeker et al., 2012)
oup members, and confederates,
posure itself leading to a greater impact on the results from this than from themanipulation
l., 2012),
Fig. 6. Overview of research on the role of the glutamatergic system in extinction.
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GABAA receptor α2- and β2 subunit mRNA and levels of the GABA-
synthesizing enzyme glutamate decarboxylase (GAD) and the GABA
transporter GAT1 (Heldt & Ressler, 2007). Further demonstrating the
importance of GABAergic signaling to extinction, fear extinction learn-
ing is disrupted by mutation-induced deﬁcits in the activity-
dependent GAD isoform GAD65 (Sangha et al., 2009), and by viral
knock-down of the constitutive GAD isoform GAD67 (Heldt et al.,
2012). While these ﬁndings suggest that upregulation of GABAergic
signaling supports extinction, GABAA receptor antagonists such as pic-
rotoxin or bicuculline can enhance extinctionmemorieswhen adminis-
tered systemically (McGaugh et al., 1990), or when infused into the BLA
(Berlau &McGaugh, 2006) or speciﬁc (fear promoting) areas (PL) of the
mPFC (Fitzgerald et al., 2014b; Thompson et al., 2010). The reason for
these apparent contradictions is not yet clear.Preliminary ﬁndings from studies using genetically modiﬁed mice
suggest that the development of subunit-selective GABAA receptor
drugs could be a promising way to more distinctly utilize GABAergic
mechanisms facilitating extinction. For example, there is reduced
mRNA expression of α5 and γ1 subunits in the AMY of a mouse
model of enhanced anxiety (Tasan et al., 2011) displaying impaired ex-
tinction (Yen et al., 2012). In addition, deletion of α5-containing GABAA
receptors in the HPC is sufﬁcient to impair fear extinction recall (Yee
et al., 2004)while global deletion of theGABAAα3 subunit producesmod-
est improvements in extinction learning (Fiorelli et al., 2008).
An additional possible explanation for some paradoxical ﬁndings
concerning GABA regulation and AMY function in extinction is the fact
that most of the prior studies have performed pharmacological or ge-
netic manipulations that affect either the entire brain, just the AMY, or
even only AMY subregions. Despite this, we now know that GABA
Table 4
Glutamatergic signaling in fear extinction (preclinical studies).
Drug/manipulation Extinction
training
Extinction
retrieval
Longterm
extinction
Route Reference
Facilitating AMPA signaling
PEPA (AMPA potentiator) No effect* No effect* ns ip (Whittle et al., 2013)
No effect* +* ns ip (Yamada et al., 2011)
+# + + (Re-in) ip (Yamada et al., 2009)
+ + ns ip (Zushida et al., 2007)
PEPA + NBQX (AMPA ant) No effect No effect ns ip (Zushida et al., 2007)
PEPA (AMPA potentiator) (+) (+) ns PL (Zushida et al. 2007)
+ + ns BLA/ceA (Zushida et al., 2007)
Inhibiting AMPA signaling
CNQX (AMPA ant) ns No effect ns BLA (Falls et al. 1992; Lin et al. 2003b; Zimmerman and
Maren 2010)
Facilitating NMDA signaling
D-Cycloserine ns + ns ip (Walker et al., 2002)
ns +1 ns Systemic (Ledgerwood et al., 2003)
ns +1 + (Re-in) Systemic (Ledgerwood et al., 2004)
ns +1 ns Systemic (Ledgerwood et al., 2005)
ns +1 ns ip (Parnas et al., 2005)
ns + ns ip (Yang and Lu, 2005)
ns + ns ip (Lee et al., 2006)
ns + No effect sc (Woods and Bouton 2006)
ns + ns sc (Werner-Seidler and Richardson, 2007)
ns + ns Systemic (Weber et al., 2007)
ns + ns ip (Yang et al., 2007)
ns + ns ip (Yang et al., 2007)
ns + ns ip (Hefner et al., 2008)
ns + ns po (Yamamoto et al. 2008)
ns + ns ip (Matsumoto et al., 2008)
+ + ns ip (Silvestri and Root, 2008)
ns + ns sc (Langton and Richardson, 2008)
ns + No effect sc (Bouton et al., 2008)
ns + ns ip (Lin et al., 2010)
+# + + (Re-in) ip (Yamada et al., 2009)
+ ns ns ip (Lehner et al., 2010)
ns +1 ns Systemic (Langton and Richardson, 2010)
No effect* +* ns ip (Yamada et al., 2011)
No effect + ns ip (Toth et al., 2012b)
ns +1 ns ip (Toth et al., 2012b)
ns + ns Systemic (Gupta et al., 2013)
ns + ns ip (Matsuda et al., 2010)
+ + ns ip (Bai et al., 2014)
ns +1* ns ip (Whittle et al., 2013)
ns + ns BLA (Walker et al., 2002)
ns +1 ns BLA (Ledgerwood et al., 2003)
ns + ns BLA (Lee et al., 2006)
ns + ns BLA (Mao et al., 2008)
ns + ns BLA (Lee et al., 2006)
ns + ns BLA (Akirav et al., 2009)
ns No effect ns BLA (Bolkan & Lattal, 2014)
ns + ns HPC (Bolkan & Lattal, 2014)
ns + ns HPC (Ren et al., 2013)
Spermidine ns +1 ns HPC (Gomes et al., 2010)
Inhibiting NMDA signaling
MK-801 (non-competitive NMDA ant) ns − ns Systemic (Baker & Azorlosa, 1996); (Storsve et al., 2010)
ns ns + (Re-in) sc (Johnson et al., 2000)
ns −1 ns ip (Lee et al., 2006); (Liu et al., 2009)
ns − ns Systemic (Langton et al., 2007); (Chan & McNally, 2009)
CPP (competitive NMDA ant) No effect −5 ns ip (Santini et al., 2001); (Sotres-Bayon et al., 2007)
No effect − ns mPFC (Burgos-Robles et al., 2007)
ns −1 ns mPFC (Burgos-Robles et al., 2007)
− − ns BLA (Parsons et al., 2010)
AP-5 (competitive NMDA ant) ns − ns BLA (Falls et al., 1992)
−## − ns BLA (Lee & Kim, 1998)
ns −1 ns BLA (Lin et al., 2003a); (Laurent et al., 2008);
(Fiorenza et al., 2012)
No effect − ns BLA (Lin et al., 2003a); (Zimmerman & Maren, 2010)
ns − ns CA1 (Szapiro et al., 2003)
ns −1 ns CA1 (Fiorenza et al., 2012)
ns −1 ns mPFC (Fiorenza et al., 2012)
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Table 4 (continued)
Drug/manipulation Extinction
training
Extinction
retrieval
Longterm
extinction
Route Reference
Inhibiting NMDA signaling
ifenprodil (non-comp NR2B-NMDA ant) − − ns ip (Sotres-Bayon et al., 2007)
ns −1 ns Systemic (Sotres-Bayon et al., 2009)
− − ns BLA (Sotres-Bayon et al., 2007); (Laurent &
Westbrook, 2008); (Laurent et al., 2008)
ns No effect1 ns BLA (Laurent et al., 2008); (Laurent & Westbrook,
2008); (Sotres-Bayon et al., 2009)
No effect − ns mPFC (Laurent & Westbrook, 2008)
No effect No effect ns mPFC (Sotres-Bayon et al., 2009)
No effect −1 ns mPFC (Laurent & Westbrook, 2008); (Sotres-Bayon
et al., 2009)
ns −1 ns HPC (Gomes et al., 2010)
Ro25-6981 (non-comp NR2B-NMDA ant) − No effect ns ip (Dalton et al., 2008, 2012)
Facilitating mGluR signaling
CDPPB (mGluR5 pos modulator) +3 ns ns sc (Gass & Olive, 2009)
AMN082 (mGluR7 ag) +* +* ns ip (Whittle et al., 2013)
ns + ns po (Fendt et al., 2008)
− No effect ns ip (Toth et al., 2012b)
ns −1 ns ip (Toth et al., 2012b)
(+) No effect ns BLA (Dobi et al., 2013)
− − ns mPFC (Morawska & Fendt, 2012)
Inhibiting mGluR signaling
CPCCOEt (non-comp mGluR1 ant) − − ns BLA (Kim et al., 2007)
No effect No effect No effect (SR) ip (Mao et al., 2013)
mGluR4 KO ns + ns No drug (Davis et al., 2013)
mGluR5 KO − − ns No drug (Xu et al., 2009)
MTEP (mGluR5 ant) No effect − − (SR) ip (Mao et al., 2013)
ns ns − (SR) BLA (Mao et al., 2013)
MPEP (allosteric mGluR5 ant) No effect No effect ns ip (Toth et al., 2012b)
ns No effect1 ns ip (Toth et al., 2012b)
No effect − ns ip (Fontanez-Nuin et al., 2011)
No effect − ns IL (Fontanez-Nuin et al., 2011)
− − ns IL (Sepulveda-Orengo et al., 2013)
mGluR7 KO −4 ns ns No drug (Callaerts-Vegh et al., 2006); (Goddyn et al.,
2008)
+ + ns No drug (Fendt et al., 2013)
siRNA knock-down of mGluR7 −2 ns ns No drug (Fendt et al., 2008)
mGluR8 KO No effect# No effect ns No drug (Fendt et al., 2013)
(S)-3,4-DCPG (mGluR8 ag) − No effect ns BLA (Dobi et al., 2013)
1Drug administration following extinction training; 2conditioned taste aversion; 3 cocaine conditioned place preference; 4 food-rewarded operant conditioning, 5 reduced locomotion.
* Facilitates rescue of impaired fear extinction; # reduced fear expression at the beginning of extinction training; ## enhanced fear expression at the beginning of extinction training.
+, Improved;−, impaired; (+) or (−), only minor effects; po, peroral administration; ip, intraperitoneal injection; sc, subcutaneous injection; ns, not studied; BLA, intra-basolateral
amygdala administration; HPC, hippocampus; IL, infralimbic cortex; SR, spontaneous recovery; Re-in, reinstatement; ag, agonist; ant, antagonist, KO, knock-out;
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subregion-speciﬁc manipulation is likely to affect many different cell
populationswhichmay have opposing functional effects. One recent at-
tempt to address this complexity involved the use of an inducible
GABAa1 knockout strategy limited only to the corticotropin-releasing-
hormone containing neuronal population (Gafford et al., 2012)),
which revealed relatively speciﬁc effects, including enhanced anxiety
and extinction deﬁcits. It is likely that future studies aimed at cell-type
speciﬁc manipulations will help address the vast complexity of the
many different cell types combined with the large number of different
GABA receptor populations.
Asmentioned above, themultiple different binding sites foundwith-
in GABAA receptors can be used to elicit a more nuanced modulation of
GABAA receptor activity. Positive allosteric modulation of GABAA recep-
tor activity via BZD, represents the most widely described drug-based
strategy for acute treatment of anxiety states (Macaluso et al., 2010).
The prevalence of BZD use among patients suffering frommental disor-
ders is high, and is estimated to range between 40 and 70% of these pa-
tients (Clark et al., 2004) However anxiolytic treatment with BZDs is
recommended only for short periods of time, due to several disadvan-
tages including its sedative effects, the development of dependence
and difﬁculties with discontinuing chronic treatment (Otto et al.,
2002). The sedating and calming effects of BZDs might in fact interfere
with extinction possibly via reduced arousal and decreased release of
neurochemicals (e.g. noradrenaline) and stress hormones (e.g.glucocorticoids) that support extinction [(Bentz et al., 2010), see
Section 4.8Glucocorticoids) for details]. BZDsmay also render extinction
memories dependent on the drug-induced internal anxiolytic-state
(state dependent learning), which upon BZD discontinuation may no
longer be accessible. These concerns are borne out by preclinical data
showing that systemic (Bouton et al., 1990; Bustos et al., 2009;
Goldman, 1977; Hart et al., 2009, 2010, 2014; Pereira et al., 1989) or
intra-BLA (Hart et al., 2009, 2010) BZD administration impairs extinc-
tion (Table 5), presumably also through state-dependent mechanisms.
Systemic treatment with a BZD inverse agonist (Harris & Westbrook,
1998; Kim & Richardson, 2007, 2009) has similar effects (see Table 5
for a summary]. Hence, combining BZD with CBT needs careful consid-
eration. As well as further development of BZDs targeting speciﬁc sub-
units of the GABAA receptor [reviewed in (Griebel & Holmes, 2013)],
which provides some hope, there is preliminary evidence that putative
novel anxiolytics that do not impair extinction learning [e.g. neuropep-
tide S; (Slattery et al., in press) see Section 4.7Neuropeptides] can be de-
veloped to help reduce patients' aversion to the unpleasant and
demanding procedure of recalling details of their traumatic memories,
thus increasing their willingness to interact with the psychotherapist.
In contrast to the relatively large number of studies of the GABAA re-
ceptor, only a few studies have investigated the role of GABAB receptors.
Functional GABAB receptors are heterodimers containing a GABAB1 and
a GABAB2 subunit; the GABAB1 subunit has two isoforms—GABAB1a and
GABAB1b (Fritschy et al., 1999). While functional deletion of GABAB
Table 4A
Human trials: D-cycloserine (DCS) combined with CBT.
Disorder Study design Outcome (compared to placebo control group) Reference
Healthy volunteers DCS or placebo 2–3 h prior extinction training No effect on fear extinction or fear recovery in healthy
volunteers
(Guastella et al., 2007)
Healthy volunteers DCS, placebo, valproic acid or combination of DCS
and valproic acid 1.5 h prior extinction training
Administration of DCS, valproic acid or DCS/valproic
acid combination facilitates fear extinction and
protects from reinstatement
(Kuriyama et al., 2011)
Healthy volunteers DCS or placebo 2 h prior extinction training No effect on extinction learning and retention in
healthy volunteers
(Klumpers et al., 2012)
Acrophobia DCS or placebo 1 h prior 2 sessions of virtual reality
exposure
3 month follow-up
Reduced fear symptoms in DCS group at all timepoints (Ressler et al., 2004)
Acrophobia 2 sessions virtual reality exposure plus DCS or
placebo after the sessions
1 month follow-up
Re-evaulation of (Tart et al., 2013)
No advantage of DCS over placebo augmented VRE
DCS effect depends on success of exposure sessions
(within-session fear reduction)
(Tart et al., 2013)
(Smits et al., 2013a)
Snake phobia DCS or placebo 1 h prior a single exposure session Same level of improvement with DCS, but DCS group
achieved fear reduction quicker
(Nave et al., 2012)
Panic disorder DCS or placebo 1 h prior CBT session 3–5
1 month follow-up
DCS group showed greater reduction in panic
symptom severity at all timepoints
(Otto et al., 2010c)
Panic disorder with agoraphobia DCS or placebo 1 h prior 3 individual exposure
sessions + 8 group CBT sessions 5 months
follow-up
No beneﬁts of DCS at all timepoints, but initial
beneﬁcal effects in severely symptomatic patients?
(Siegmund et al., 2011)
PTSD DCS or placebo 1 h prior 10 weekly exposure
sessions
No overall enhancement of treatment effects.
Higher symptom reduction in severe cases.
(de Kleine et al., 2012)
PTSD
(combat-related)
DCS or placebo 30 min prior exposure session 2–6 Weaker symptom reduction compared to placebo
group
(Litz et al., 2012)
PTSD DCS or placebo 1.5 h prior 12 weekly VRE session 6
months follow-up
DCS group showed earlier and greater improvement as
well as higher remission rates
(Difede et al., 2014)
pediatric PTSD DCS or placebo 12 1 h prior session 5–12 No difference in symptom reduction, DCS group
showed trend for faster response and better retention
in 3 month follow-up
(Scheeringa & Weems, 2014)
SAD 1× psychoeducation; DCS or placebo 1 h prior to 4 h
exposure session (5×, individual or group)
1 month follow-up
Decreased self-reported social anxiety symptoms in
DCS group after 1 month
(Hofmann et al., 2006)
SAD DCS or placebo 1 h prior to 4 h exposure therapy
(5×)
Fewer social fear and avoidance in DCS group.
Signiﬁcant differences in DCS vs placebo following 3rd
exposure session.
(Guastella et al., 2008)
SAD DCS or placebo with CBT Greater overall rates of improvement and lower
post-treatment severity
(Smits et al., 2013b)
SAD 12 weeks; DCS or placebo 1h prior 5 exposure
sessions (12 sessions at all); 6-months follow-up
Similar response and remission rates, DCS group
improved quicker
(Hofmann et al., 2013b)
OCD D-Cycloserine (DCS) or placebo 4 h prior each
exposure session, 12 weeks (one exposure
session/week)
No statistically signiﬁcant difference.
High response rates in treatment and placebo group.
(Storch et al., 2007)
OCD 2×/week DCS or placebo 2 h prior exposure and
response prevention (ERP) sessions
(max 10)
3 months follow-up
Faster improvements in DCS group
No difference between DCS and placebo group
(no further beneﬁt).
(Kushner et al., 2007)
OCD 2×/week DCS or placebo 1 h prior 10 ERP sessions
1 month follow-up
Re-evaluation of Wilhelm et al., 2008
Faster improvements in DCS group
No difference between DCS and placebo group
(no further beneﬁt).
Speciﬁc improvements of DCS in the ﬁrst 5 sessions,
6× faster than placebo group
(Wilhelm et al., 2008)
(Chasson et al., 2010)
Pediatric OCD DCS or placebo 1 h prior weekly session 4–10
(psychoeduction, cognitive training and ERP) for 10
wks
Modest reduction of obsessive symptoms (Storch et al., 2010)
Pediatric OCD DCS or placebo 1 h prior session 5–9 ERP-CBT Signiﬁcant improvements in OCD severity from
posttreatment to 1-month follow-up in severe and
difﬁcult-to-treat pediatric OCD
(Farrell et al., 2013)
Pediatric OCD DCS or placebo immediately after each of 10 CBT
(ERP) sessions
1 year follow-up
both groups improved;
no signiﬁcant advantage of DCS at any timepoint
(Mataix-Cols et al., 2014)
166 N. Singewald et al. / Pharmacology & Therapeutics 149 (2015) 150–190receptors (GABAB1a/b knock-out) impairs extinction learning (Jacobson
et al., 2006), pharmacological GABAB receptor antagonism does not
(Heaney et al., 2012; Sweeney et al., 2013). Systemic administration of
(non-selective) agonists or positive allosteric modulators of GABAB
signaling also has inconsistent effects (impairing or negative) on
extinction [(Heaney et al., 2012; Sweeney et al., 2013) see Table 5]. A
ﬁnal answer to this question regarding the role of GABAB receptors
may have to await the availability of GABAB1a-and GABAB1b-selective
compoundsTaken together, the available evidence indicates that GABA signaling
has a major, but spatially and temporally restricted role in the formation
of fear extinction memories. While GABA that is engaged during extinc-
tion is likely to support synaptic plasticity, increasing GABAergic tone
globally seems to limit the efﬁcacy of extinction-based therapies by
mechanisms outlined above. Therefore, it is unlikely that drugs broadly
targeting the GABA systemwill be useful in this respect. Pharmacological
adjuncts to exposure therapy targeting the GABA system would rather
need to strike a balance between driving and maintaining relevant
Fig. 7. Overview of research on the role of the GABAergic system in extinction.
167N. Singewald et al. / Pharmacology & Therapeutics 149 (2015) 150–190GABA activity without over-activating the system. The evidence so far
suggests that subunit-selective or allosteric (distinct from BZD) modula-
tion of GABAA receptor signaling may hold promise in this regard.
4.6. Cannabinoids
A growing body of literature demonstrates that the endogenous can-
nabinoid (eCB) system modulates neuronal excitability in stressful and
fearful situations (de Bitencourt et al., 2013; Gunduz-Cinar et al.,
2013a). eCB signaling has been implicated in emotional and cognitive
processing of threatening stimuli, for instance during the consolidationof fear and fear extinction memories (for more detailed recent reviews
see (Riebe et al., 2012; Gunduz-Cinar et al., 2013b). Upon neuronal
activation, an eCB (anandamide) and 2-arachidonoylglycerol (Fig. 8)
are rapidly synthesized in the postsynaptic neuron (within minutes)
and released into the synaptic cleft to modulate presynaptic signaling
by the activation of Gi/0-coupled CB-1 receptors (CB-2 receptors are
mainly expressed on immunecells, osteoblasts, osteoclasts and hemato-
poietic cells but also on neuroglia).
Supporting a role of eCB signaling in the extinction of aversive mem-
ories (see Fig. 8 for overview), there are increased eCB levels in the
mouse BLA following extinction training (Marsicano et al., 2002).
Table 5
GABAergic signaling in fear extinction (preclinical studies).
Facilitating GABA signaling
Drug/manipulation Extinction training Extinction retrieval Longterm extinction Route Reference
GABAA agonists GABA-binding site (αβ interface)
Muscimol +# No effect ns BLA (Akirav et al., 2006)
ns +1,7 ns BLA (Akirav et al., 2006)
−# − ns BLA (Laurent et al., 2008), (Laurent & Westbrook, 2008)
ns −1 ns BLA (Laurent & Westbrook, 2008)
(+)# − ns BLA (Sierra-Mercado et al., 2011)
− − ns mPFC (Laurent & Westbrook, 2008)
ns −1 ns mPFC (Laurent & Westbrook, 2008)
ns No effect1, ns IL (Akirav et al., 2006)
+# (+) ns IL (Akirav et al., 2006)
− − ns IL (Sierra-Mercado et al., 2011)
No effect − ns IL (Laurent & Westbrook, 2009)
(+)# No effect ns PL ((Laurent & Westbrook, 2009); (Sierra-Mercado et al.,
2011))
ns ns + (Ren-A)8 dHPC (Corcoran et al., 2005)
− − No effect (Ren-A) dHPC (Corcoran et al., 2005)
(+)# − ns vHPC (Sierra-Mercado et al., 2011)
GABAA: agonists BZD-binding site αγ interface)
Chlordiazepoxide − ns ns ip (Goldman, 1977)
ns − ns ip (Bouton et al., 1990)
Diazepam ns − ns ip (Pereira et al., 1989)
ns − ns ip (Bouton et al., 1990)
Midazolam ns −1 ns ip (Bustos et al., 2009)
−##6 − ns ip (Hart et al., 2009, 2010), (Hart et al., 2014)
−#6 − ns BLA (Hart et al., 2009, 2010, 2014)
GABAB receptor agonists
Baclofen ns − ns ip (Heaney et al., 2012)
GS39783 (positive modulator GABAB) ns No effect ns po (Sweeney et al., 2013)
Inhibiting GABA signaling
Drug/manipulation Extinction learning Extinction retrieval Longterm extinction Route Reference
GAD67 KD in BLA − ns ns No drug (Heldt et al., 2012)
GAD65 KO −2 −2 ns No drug (Sangha et al., 2009)
α5 KD in HPC ns −3 ns No drug (Yee et al., 2004)
α1 KO in CRF+ cells − − ns No drug (Gafford et al., 2012)
Picrotoxin ns + ns ip (McGaugh et al., 1990)
ns +4 ns IL (Thompson et al., 2010)
ns +4 ns PL (Thompson et al., 2010)
ns +* ns (Fitzgerald et al., 2014b)
Bicuculline ns +1 ns BLA (Berlau & McGaugh, 2006)
Bicuculline + propanolol ns No effect1 ns BLA (Berlau & McGaugh, 2006)
FG7142 − − ns ip (Harris & Westbrook, 1998)
ns − ns ip (Kim & Richardson, 2007, 2009)
GABAB receptor antagonism
GABAB(1b) KO −5 ns ns No drug (Jacobson et al., 2006)
Phaclofen ns No effect ns ip (Heaney et al., 2012)
CGP52432 ns No effect ns po (Sweeney et al., 2013)
1 Drug administration following extinction training; 2 only cuedmemory, contextual intact, 3 trace conditioning, 4 reconsolidation (injection prior reactivation of memory), 5 conditioned
taste aversion, 6 midazolam may not impair fear extinction if initial extinction occurs drug-free [see (Hart et al., 2014)], 7 short extinction training (5 CS presentations), 8 injection prior
renewal-testing.
# Reduced fear expression at start of extinction training; ## enhanced immobility at start of extinction training;
+, Improved;−, impaired; (+) or (−), only minor effects; ip, intraperitoneal injection; po,peroral administration; ns, not studied; HPC, intra-hippocampal administration; BLA, intra-
basolateral amygdala administration; IL, infralimbic cortex; PL, prelimbic cortex; Ren-A, Fear renewal in conditioning context; ag, agonist; ant, antagonist, KO, knock-out;
168 N. Singewald et al. / Pharmacology & Therapeutics 149 (2015) 150–190Conversely, PTSD patients show low brain anandamide levels
(Neumeister et al., 2013). In rodents, facilitation of eCB signaling by CB-
1 receptor agonists or exogenous cannabinoids [cannabidiol, (Bitencourt
et al., 2008)], reuptake inhibitors [AM404, (Bitencourt et al., 2008;
Chhatwal et al., 2005b; Pamplona et al., 2008)] or anandamide degrada-
tion blockers [AM3506, URB 597, (Gunduz-Cinar et al., 2013b)] enhances
the formation or consolidation of extinction memories. Blockade or
knock-out of CB1-receptors (Cannich et al., 2004; Kamprath et al., 2006;
Marsicano et al., 2002; Niyuhire et al., 2007; Pamplona et al., 2006;
Plendl &Wotjak, 2010; Reich et al., 2008; Terzian et al., 2011) impairs ex-
tinction and blocks the pro-extinction effects of drugs that facilitate eCB
transmission (Chhatwal et al., 2005b; Do Monte et al., 2013;
Gunduz-Cinar et al., 2013b) (see Table 6). Collectively, these observationspoint to CB-1 receptormediated eCB signaling as a powerfulmodulator of
extinction.
Following up on these studies, intra-cerebral infusions of CB1-
receptor agonists and antagonists have revealed a potential role of
mPFC-BLA eCB signaling in extinction [see Table 6, (Do Monte et al.,
2013; Ganon-Elazar & Akirav, 2013; Gunduz-Cinar et al., 2013b)]. CB1-
receptor activation inhibits both presynaptic glutamate and GABA
release. The release of anandamide and concomitant CB1-receptor
activation induce long-term depression of inhibitory transmission
(LTDi) in the BLA (Azad et al., 2004; Gunduz-Cinar et al., 2013b). In
addition, a recent study demonstrated that enhanced inhibitory input
via activation of CB1 receptor expressing cholecystokinin (CCK) positive
interneurons selectively reduces ﬁring of BLA fear neurons and
Fig. 8. Overview of research on the role of the cannabinoid system in extinction.
169N. Singewald et al. / Pharmacology & Therapeutics 149 (2015) 150–190promotes extinction (Trouche et al., 2013). Of note is the fact that it
has also been shown that one potential mechanism for the CB1 effect
on extinction within the AMY is via blockade of CCK release, as an intra-
AMY CCK antagonist reversed the extinction blockade of systemic CB1
antagonists, and CCK agonists block extinction (Chhatwal et al., 2009).
In summary, current preclinical data suggest that eCB signaling gates
BLA function through plastic changes, including a long-lasting depres-
sion of inhibition, to modulate extinction-related AMY activity. Initial
results from clinical studies in healthy volunteers suggest that exoge-
nous cannabinoid administration strengthens extinction and protects
against reinstatement [see Table 6A, (Das et al., 2013; Rabinak et al.,
2013)]. Future clinical trials in extinction-impaired PTSD patients will
be needed to show whether cannabinoids (or substances which in-
crease endogenous eCB signaling, such as FAAH inhibitors) might
prove useful as adjuncts to CBT-based therapy.
4.7. Neuropeptides (oxytocin, neuropeptide Y, neuropeptide S, opioids)
Various neuropeptides and their corresponding receptors are local-
ized in brain regionsmediating emotional behavior and stress response
and have been considered as potential anxiolytic drug targets (Bowerset al., 2012; Ebner et al., 2009; Griebel & Holmes, 2013). While other
neuroptides such as hypocretin/Orexin (Flores et al., 2014) may also
be involved in fear extinction, we will here address the role of oxytocin,
neuropeptide Y, neuropeptide S and opioids in extinction.
4.7.1. Oxytocin
The oxytocin (OXT) system, strongly implicated in social cognition
and behavior, is posited to play a role in anxiety disorders with impaired
social functioning (Meyer-Lindenberg et al., 2011; Neumann& Landgraf,
2012). OXT is synthesized in the paraventricular (PVN) and supraoptic
nuclei of the hypothalamus and processed along the axonal projections
to the posterior pituitary gland. Uponneuronal activationOXT is released
from secretory vesicles into the peripheral circulation as neurohypophy-
seal hormone. The central nervous system (CNS) component of OXT is
derived from dendritic release of the same cell population (Ludwig &
Leng, 2006), as well as from the OXT-synthesizing parvocellular PVN
cells sending projections throughout the brain [reviewed in (Gimpl &
Fahrenholz, 2001)]. OXT receptors are typically Gq-protein coupled and
have potential allosteric binding sites for Mg2+ and steroids like choles-
terol. The distribution of OXT receptors has not been fully delineated, but
OXT ﬁbers and neurosecretory nerve endings have been described in,
Table 6
Cannabinoid signaling in fear extinction (preclinical studies).
Enhanced cannabinoid signaling
Drug/manipulation Extnction
training
Extinction
retrieval
Longterm
extnction
Route Reference
Cannabidiol + + ns icv (Bitencourt et al., 2008)
+ + ns IL (Do Monte et al., 2013)
Anandamide ns +1 ns dCA1 (de Oliveira Alvares et al., 2008)
AM404 (eCB uptake inhibitor) ns + ns ip (Pamplona et al., 2008)
ns + + (Re-in) ip (Chhatwal et al., 2005b)
+ (+) ns icv (Bitencourt et al., 2008)
No training + ns IL (Lin et al., 2009)
AM3506 (FAAH inhibitor) ns + ns ip (Gunduz-Cinar et al., 2013b)
WIN 55,212-2 (low-dose CB1 Ag) +* No effect2 ns ip (Pamplona et al., 2006)
WIN 55,212-2 (high-dose CB1 Ag) (−)* No effect2 ns ip (Pamplona et al., 2006)
WIN 55,212-2 (CB1 Ag) +° +° ns ip (Pamplona et al., 2006)
ns + nd ip (Pamplona et al., 2008)
WIN 55,212-2 (CB1 Ag) ns +4 ns BLA (Ganon-Elazar & Akirav, 2013))
ns +4 ns HPC (Ganon-Elazar & Akirav, 2013)
ns No effect4 ns mPFC (Ganon-Elazar & Akirav, 2013)
ns + No effect (Re-in,
SR3)
IL (Lin et al., 2009)
No training + ns IL (Lin et al., 2009)
ns No effect ns PL (Kuhnert et al., 2013)
HU210 No training + ns IL (Lin et al., 2009)
URB597 (AEA hydrolysis inhibitor) No training + ns IL (Lin et al., 2009)
AM3506 (FAAH inhibitor) + SR141716A
(CB1 ant)
ns No effect ns ip + BLA (Gunduz-Cinar et al., 2013b)
AM3506 (FAAH inhibitor) ns + ns BLA (Gunduz-Cinar et al., 2013b)
No training No effect ns BLA (Gunduz-Cinar et al., 2013b)
Cannabidiol + SR141716A (CB1 ant) No effect No effect ns IL + ip (Do Monte et al., 2013)
Reduced cannabinoid signaling
Drug/manipulation Extnction
learning
Extinction
retrieval
Longterm
extinction
Administrationroute Reference
CB1 KO − − ns No drug (Cannich et al., 2004)
CB1 KO − ns ns No drug ((Dubreucq et al., 2010); (Kamprath et al., 2006);
(Marsicano et al., 2002); (Plendl & Wotjak, 2010))
D1-CB1 KO − ns ns No drug (Terzian et al., 2011)
SR141716A CB1 ant ns No effect1 ns sc (Marsicano et al., 2002)
− ns ns sc, ip ((Kamprath et al., 2006); (Niyuhire et al., 2007);
(Plendl & Wotjak, 2010)
ns −1 ns ip (Suzuki et al., 2004)
− No effect ns ip (Pamplona et al., 2006, 2008)
ns − ns ip (Chhatwal et al., 2005b)
−## No effect ns ip (Bowers & Ressler, 2015)
AM251 (CB1 inverse ag) − ns ns ip (Reich et al., 2008)
ns −1 ns dCA1 (de Oliveira Alvares et al., 2008)
ns − ns IL (Lin et al., 2009)
No training No effect ns IL (Lin et al., 2009)
ns − ns PL (Kuhnert et al., 2013)
1 Drug administration following extinction training; 2 drug-free retrieval of contextual fear memory; 3 5 days, 4 single-prolonged-stress model: injection immediately after trauma.
*, Recent memory; °, remote memory; ##, enhanced immobility at start of extinction training;
+, Improved;−, impaired; (+) or (−), onlyminor effects; ip, intraperitoneal injection; ip, sc, subcutanous injection; ns, not studied; HPC, intra-hippocampal administration; BLA, intra-
basolateral amygdala administration; IL, infralimbic cortex; PL, prelimbic cortex; CA1, cornu ammonis 1; Re-in, reinstatement; SR, spontaneous recovery, ag, agonist; ant, antagonist, KO,
knock-out;
170 N. Singewald et al. / Pharmacology & Therapeutics 149 (2015) 150–190among other regions, the AMY [especially CeL (Knobloch et al., 2012;
Veinante & Freund-Mercier, 1997)], the dorsal and ventral HPC and the
main monoamine nuclei – substantia nigra (dopamine), raphe nuclei
(serotonin) and the locus coeruleus (noradrenaline) [see (Gimpl &
Fahrenholz, 2001) for review).Table 6A
Human trials: cannabinoids combined with CBT.
Disorder Study design
Healthy volunteers Fear conditioning paradigm, cannabidiol inhalation prior or
following extinction
Healthy volunteers Fear conditioning paradigm, tetrahydro-cannabinol prior extinctio
Healthy volunteers Fear conditioning paradigm, Dronabinol prior extinctionRegulatory effects of OXT on stress-induced activation of the
hypothalamic–pituitary–adrenal (HPA) axis, as well as direct OXT ef-
fects on the brain and speciﬁc parts of the extinction circuitry, can affect
fear extinction in variousways. Intracerebroventricular (icv) infusion of
OXTprior to fear conditioning does not affect fear learning but facilitatesOutcome (compared to placebo control group) Reference
Reduced fear in retrieval
Protection against reinstatement
(Das et al., 2013)
n No effect (Klumpers et al., 2012)
Reduced fear in retrieval (Rabinak et al., 2013)
171N. Singewald et al. / Pharmacology & Therapeutics 149 (2015) 150–190later extinction acquisition and retrieval (Toth et al., 2012a). Conversely,
OXT receptor antagonists impair extinction learning and retrieval when
administered icv prior to fear acquisition (Toth et al., 2012a). More lo-
calized OXY infusions into the central CeA reduce fear expression by
inhibiting CeM excitatory output to fear-eliciting brainstem structures
(Huber et al., 2005) (Viviani et al., 2011), suggesting one possible
mechanism for the effects of icv OXY on extinction.
Another potential mechanismmight be OXT-induced dampening of
stress-induced activation of the HPA axis (de Oliveira et al., 2012;
Heinrichs et al., 2003; Quirin et al., 2011; Windle et al., 1997). As
explained inmore detail in Section 4.8Glucocorticoids, glucocorticoid re-
lease during an actual learning process facilitates cognitive processing
[reviewed in (Bentz et al., 2010)], hence the release of endogenous
OXT during traumatic experiences (Zoicas et al., 2012) may interfere
with the consolidation of fear memories. Along these lines, OXT-
mediated reduction ofHPA axis activity and subsequent lower glucocor-
ticoid levels could interfere with fear acquisition, resulting in a weaker
fear memory that is more susceptible to extinction training. In this con-
text, OXT administration either icv or intra BLA prior to extinction train-
ing disrupts extinction learning [(Toth et al., 2012a) (Lahoud &Maroun,
2013) see Table 7 for summary]. OXT infusions into the dorsolateral sep-
tum prior to extinction training have the opposite effect and facilitate
extinction learning and retrieval in a social fear conditioning paradigm
that may recruit a somewhat different neural circuitry than non-social
forms of fear (Zoicas et al., 2012).
Considering that systemically applied neuropeptides do not cross
the blood–brain-barrier, clinical use of neuropeptides would require a
direct pathway to the human brain. In the case of OXT, this may be fea-
sible via intranasal administration (Born et al., 2002). Intranasal OXT ad-
ministration has been demonstrated to reduce stress-induced cortisol
release in humans (de Oliveira et al., 2012; Heinrichs et al., 2003;
Quirin et al., 2011), and to attenuate AMY hyperactivity as well as
AMY-hindbrain coupling in anxiety patients [(Kirsch et al., 2005;
Labuschagne et al., 2010)]. In a recent study investigating the effects of
intranasal OXT treatment on fear extinction in healthy volunteers,
OXT increased initial fear expression during extinction training,Table 7
Neuropeptide signaling in fear extinction (preclinical studies).
Neuropeptides
Drug/manipulation Extinction training Extinction retrieval
Oxytocin − ns
+# +
−*5 −*5
Chronic oxytocin (30d) ns No effect*6
NPY + +
NPY KO −3⁎⁎⁎ −
NPY Y1 KO − No effect
NPY Y2 KO No effect No effect
NPY Y1/Y2 KO − −
Leu31Pro-NPY (Y1 ag) ns +
BIBO 3304 (Y1 ant) ns −
NPS (+)4 No effect
+ ns
SHA68 (NPS-R ant) −4, ⁎⁎⁎ −
Naloxone − −
ns No effect1
− −
− −
No effect No effect
CTAP (MOR ant) − −
Dynorphin KO −3 −
nor-BNI (KOR ant) ns −1
1 Drug administration following extinction training; 2 social fear conditioning;3 animals show a
stress model; 6 BTBR mouse autism model and C57BL6J.
*** Enhanced fear expression at the beginning of extinction training, # reduced fear expression
+, Improved;−, impaired; (+) or (−), only minor effects; ip, intraperitoneal injection; icv, in
BLA, intra-basolateral amygdala administration; DLS, dorsolateral septum; vlPAG, ventrolat
antagonist, KO, knock-out;but this effect was gone by the end of training and there was a lower
level of fear in the OXT treated group in extinction retrieval (Acheson
et al., 2013). These data raise the prospect of OXT-augmented CBT
effectiveness.4.7.2. Neuropeptide Y
Neuropeptide Y (NPY) contains 36 amino acids and is the most
widely expressed neuropeptide in themammalian brain. There are par-
ticularly high concentrations of NPY in the limbic system, including in
the AMY, the HPC and the periaqueductal gray. Six G-protein coupled
NPY receptors (Y1–6) have been identiﬁed, among which Y1, Y2, Y4,
and Y5 mediate central effects. Y1 mRNA is present at a high level in
brain areas involved in memory processing, namely the AMY, HPC,
thalamus, hypothalamus, and the cerebral cortex. The AMY, HPC, and
hypothalamus are also rich in Y2 receptors, while Y5 receptors can be
detected in HPC, cingulate cortex and thalamic and hypothalamic nuclei
(Parker & Herzog, 1999) [reviewed in (Holmes et al., 2003)].
Icv administration of NPY facilitates extinction learning (Gutman
et al., 2008), while genetic deletion of NPY disrupts extinction acquisi-
tion and subsequent retrieval (Verma et al., 2012). Extinction deﬁcits
caused by NPY knock-out are rescued by AAV-mediated NPY re-
expression in the BLA (Verma et al., 2012), where NPY co-localizes
with GABAergic neuronsmodifying inhibitory control of BLA projection
neurons (McDonald&Pearson, 1989). To elucidatewhichNPY receptors
mediate the BLA-associated effects on extinction, the consequences
of gene deletion via either deletion of Y1 or Y2 receptors or double
Y1/Y2 deletion have been examined. Deletion of Y1 receptors impaired
extinction learning, while Y2 receptor deletion had no effect (Verma
et al., 2012). Underscoring the importance to extinction of Y1 receptors
in the BLA, local infusion of the Y1 agonist Leu31Pro34-NPY prior to ex-
tinction training led to stronger extinction retrieval (Gutman et al.,
2008; Lach & de Lima, 2013). Further studies are required to further
delineate the underlying mechanisms of Y1-mediated facilitation of
extinction, and to investigate the potential clinical use of NPY and Y1
receptor agonism as adjunctive therapy to CBT.Longterm extinction Route Reference
ns icv (Toth et al., 2012a)
ns DLS (Zoicas et al., 2012)
ns ip (Eskandarian et al., 2013)
ns in (Bales et al., 2014)
ns icv (Gutman et al., 2008)
ns No drug (Verma et al., 2012)
ns No drug (Verma et al., 2012)
ns No drug (Verma et al., 2012)
ns No drug (Verma et al., 2012)
ns BLA (Lach & de Lima, 2013)
ns BLA (Gutman et al., 2008)
No effect BLA (Jungling et al., 2008)
ns icv (Slattery et al., in press)
− (Ren-A) BLA (Jungling et al., 2008)
ns Systemic (McNally & Westbrook, 2003)
ns Systemic (McNally & Westbrook, 2003)
ns vlPAG (McNally et al., 2004)
ns vlPAG (Parsons et al., 2010)
ns BLA (Parsons et al., 2010)
ns vlPAG (McNally et al., 2005)
ns No drug (Bilkei-Gorzo et al., 2012)
ns Systemic (Bilkei-Gorzo et al., 2012)
ccelerated fear learning; 4 administration 2h prior extinction training; 5 single prolonged
at the beginning of extinction training.
tra-cerebroventricular injection; ns, not studied; HPC, intra-hippocampal administration;
eral periaqueductal gray; Ren-A, fear renewal in conditioning context; ag, agonist; ant,
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Neuropeptide S (NPS) is synthesized in neurons located adjacent to
the locus coeruleus (Xu et al., 2007) and binds to G-protein coupled NPS
receptors expressed in the BLA among other areas. Intra-BLA infusion of
exogenous NPS accelerates extinction learning, while BLA NPS receptor
antagonism (via SHA68) impairs extinction learning and retrieval and
increases fear renewal (Chauveau et al., 2012; Jungling et al., 2008)
(Table 7). NPS treatment also rescues deﬁcient extinction learning
in hyperanxious rats (Slattery et al., in press), exhibiting aberrant
cortico-AMY activation (Muigg et al., 2008). The activation of
NPS receptors in the BLA increases excitatory input to GABAergic
ITCs, thus increasing feed-forward inhibition to CeM neurons
and reducing fear expression (Meis et al., 2008; Meis et al., 2011;
Pape et al., 2010). Exogenous NPS administration is also associated
with enhanced DA release in the mPFC (Si et al., 2010), suggesting
another mechanism for strengthening extinction (see Section 4.2
Dopaminergic system).
Underscoring the translational relevance of NPS, healthy human
volunteers carrying the NPS receptor polymorphism rs324981,
which potentiates NPS efﬁcacy at the receptor, show enhanced extinc-
tion in a virtual reality fear potentiated startle paradigm (Glotzbach-
Schoon et al., 2013). Additional studies are required to assess whether
increasing NPS signaling improves extinction in anxiety patients. This
would be aided by the development of small molecule NPS receptor
agonists.
4.7.4. Opioids
The opioid peptide family comprises different members including
endorphins, enkephalins, dynorphins and hemorphins. The 3 classical
opioid receptors [μ (MOR), κ (KOR) and δ (DOR)] show heterogeneous
expression throughout the brain and are located in extinction-relevant
brain areas including the AMY, mPFC and HPC. Typically, MOR, KOR
and DORs are coupled to Gi-proteins, reducing (in most cases) net
neuronal excitability and reducing neurotransmitter release upon
activation [reviewed in (Nutt, 2014)].
There is evidence that morphine application (intended for pain
management) following an acute trauma attenuates the incidence of
PTSD at later time points (Bryant et al., 2009; Holbrook et al., 2010;
Melcer et al., 2014; Szczytkowski-Thomson et al., 2013). Aside from
this potential PTSD preventing property of opioids, several studies
have tried to determine the importance of opioids in extinction.
Systemic administration of the opioid receptor antagonist
naloxone (which has highest afﬁnity to MOR, but also inhibits
KOR and DOR) impairs extinction when given prior to extinction
training (McNally & Westbrook, 2003; McNally et al., 2004) but not
when applied after extinction training or prior to retrieval,
see Table 7). Subsequent investigations have demonstrated that
extinction-impairing effects are mediated by MORs in the PAG [as
shown with the selective MOR antagonist CTAP in the PAG (McNally,
2005; Parsons et al., 2010)].
The AMY ITCs express high levels of MOR (Busti et al., 2011),
and lesioning of MOR-expressing neurons in the ITCs following
extinction training impairs extinction retrieval (Likhtik et al., 2008),
indicating that MOR signaling in the ITCs contributes to extinction con-
solidates. Probably due to the high addiction potential of MOR agonists,
no clinical studies have investigated their potential in CBT. However,
treatment with the opioid receptor antagonist naloxone prior to
exposure therapy is associated with reduced treatment success (Arntz
et al., 1993; Egan et al., 1988), which is in accordance with preclinical
results (Table 7).
Another opioid receptor gaining attention in the ﬁeld of fear ex-
tinction is the KOR, activated by endogenous dynorphins (reviewed
in Schwarzer, 2009). Human volunteers with single nucleotide poly-
morphisms in the prodynorphin gene showed increased skin con-
ductance (a physiological measure of fear) during fear extinction
training and blunted functional connectivity between AMY andmPFC (Bilkei-Gorzo et al., 2012). Along these lines, genetic deletion
of dynorphin or systemic antagonism of KORs in rodents impairs ex-
tinction learning and reduces neuronal activity in the BLA and mPFC
(Bilkei-Gorzo et al., 2012). In contrast to these extinction-impairing
effects, systemic administration of KOR antagonists protects against
fear renewal (Cole et al., 2011) — an effect mimicked by local
infusions into the ventral HPC (Cole et al., 2013). Additional studies
will help clarify these effects and their possible relevance to clinical
use of opioidergic drugs in conjunction with exposure-based
therapies.
4.8. Glucocorticoids
Emotionally arousing experiences activate the HPA axis and the re-
lease of glucocorticoids (GCs) into the bloodstream. GCs which include
cortisol in humans, and corticosterone in rodents are lipophilic and
readily cross the blood–brain-barrier to interact with glucocorticoid
(GR) andmineralocorticoid receptors (MR) in the brain. GRs are widely
expressed throughout the brain including the AMY, HPC and PFC (Bentz
et al., 2010). Early pioneering studies reported that extinction-memory
formation is disrupted by adrenalectomy (Silva, 1973), as well as, more
recently, by compounds that antagonize GRs, such as mifepristone
(Yang et al., 2006), or that inhibit corticosterone synthesis [metapyrone,
(Barrett & Gonzalez-Lima, 2004; Blundell et al., 2011; Harrison et al.,
1990; Yang et al., 2006, 2007)] (see Table 8). Conversely, systemic ad-
ministration of corticosterone (Blundell et al., 2011) or the GR agonists
dexamethasone or RU28362 (Ninomiya et al., 2010; Yang et al., 2006,
2007) facilitate the consolidation of aversive and appetitive extinction
memories (see Table 8).
How can stress hormones promote the formation of extinction
memories? Cytosolic GRs induce genomic responses by binding to
glucocorticoid responsive elements within promoter regions of GC-
responsive genes, and act as transcription factors inducing the expres-
sion of learning-related genes. In addition, membrane-bound GRs can
induce non-genomic actions of relevance to extinction, including the
synthesis of eCBs (see Section 4.6 Cannabinoids) frommembrane phos-
pholipids (Di et al., 2003; Hill et al., 2005, 2011). Further supporting a
link between GRs and eCBs, and possibly of importance in GC-
augmented extinction consolidation, adrenalectomy leads to reduced
CB-1 receptor expression (Mailleux & Vanderhaeghen, 1993) and GC-
mediated memory consolidation is prevented by CB-1 receptor antago-
nists (Campolongo et al., 2009).
GRs can also induce indirect learning-relevant genomic actions via
activation of intracellular signaling cascades such as the ERK/MAPK
pathway (reviewed in Reul, 2014) in cooperation with other neuro-
transmitter systems or ion channels including β-adrenoceptors
(Roozendaal et al., 2008), and L-type calcium channels (Karst et al.,
2002). These interrelated effects are functionally relevant, given that
the infusion of β-adrenoceptor antagonists into the BLA blocks the
memory-facilitating effects of systemically administered glucocorti-
coids (Quirarte et al., 1997; Roozendaal et al., 2002).
Another important functional interaction occurs between GCs and
the glutamate system. GCs potentiate glutamatergic signaling via geno-
mic and non-genomic mechanisms, by (i) increasing the readily releas-
able pool of presynaptic glutamate vesicles, and (ii) enhancing NMDA
and AMPA receptor surface expression through increased receptor traf-
ﬁcking (reviewed in Popoli et al., 2012). The concomitant activation of
GC and NMDA receptors, which can occur during emotionally arousing
experiences, induces downstream nuclear mechanisms that result in
histone modiﬁcations (reviewed in Reul, 2014), an epigenetic mecha-
nism implicated in extinction (see Section 4.10: Epigenetics for details).
Underscoring the potential importance of emotional arousal and thus of
GC release in this process, pretreatment with the anxiolytic BZD loraze-
pam (resulting in reduced arousal in response to the stressor) blocked
epigenetic modiﬁcations on Histone H3, while application of the
anxiogenic BZD inverse agonist FG7142 (Singewald et al., 2003)
Table 8
Glucocorticoid signaling in fear extinction (preclinical studies).
Facilitating glucocorticoid signaling
Drug Extinction training Extinction retrieval Long-term extinction Route Reference
Corticosterone (GR/MR ag) ns +1 No effect (Re-in) ip (Blundell et al., 2011)
ns −2 ns ip (Den et al., 2014)
Dexamethasone (GR ag) ns + ns ip (Ninomiya et al., 2010); (Yang et al., 2006, 2007)
RU28362 (GR ag) ns + ns AMY (Yang et al., 2006)
Ganoxolone (allopregnanolone analog) +*3 +*3 ns ip (Pinna & Rasmusson, 2014)
Inhibiting glucocorticoid signaling
Metyrapone (CORT/cortisol synthesis inhibitor) No effect − −* sc (Barrett & Gonzalez-Lima, 2004); (Clay et al., 2011)
ns − ns sc (Blundell et al., 2011); (Yang et al., 2006, 2007)
Mifepristone (GR and progesterone ant) ns − ns AMY (Yang et al., 2006)
1 Drug administration following extinction training; 2 in adolescent but not adult rats if exposed to CORT one week prior to (drugfree) testing; adults also show impaired extinction re-
trieval if they were exposed to one week of CORT in their adolescence; 3 socially isolated mice, CAVE ganoxolone was administered following a reactivation session 24h prior extinction
training.
+, Improved;−, impaired; ip, intraperitoneal injection; sc, subcutaneous injection;ns, not studied;AMY, intra-amygdala administration; Re-in, reinstatement; ag, agonist; ant, antagonist;
GR, glucocorticoid receptor; MR, mineralocorticoid receptor; CORT, corticosteroid.
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histone tails (Papadopoulos et al., 2011). These epigenetic effects
could contribute to the aforementioned extinction impairing effects of
BZDs (see Section 4.5: γ-Aminobutyric acid (GABA) and Table 5).
In contrast to the effects of acuteGC elevations, chronic high levels of
corticosterone reduce cell-surface NMDA and AMPA receptor expres-
sion (Gourley et al., 2009). This loss of critical plasticity mechanisms
might be one explanation as to why anxiety patients with a history of
repeated traumatic events, such as combat veterans, show greater resis-
tance to treatment. However, a considerable proportion of PTSD pa-
tients have reduced cortisol levels (Yehuda, 2004) and small case
studies suggest that there are beneﬁcial effects of CBT and adjunctive
cortisol administration in PTSD patients (Yehuda et al., 2010). A
number of larger studies are under way to extend this work
(NCT01108146, NCT00751855, NCT01525680). In addition, it has
been found that cortisol-augmented CBT has efﬁcacy in acrophobia
(de Quervain et al., 2011), arachnophobia (Soravia et al., 2006,
2014) and social phobia [(Soravia et al., 2006) see Table 8A for a
summary]. Whether cortisol augmented CBT for non-phobic anxiety
disorders, including also GAD, facilitates fear inhibition is currently
being investigated in ongoing clinical studies (see Cain et al.,
2012). Furthermore, future studies may implement more selective
GC agonists than cortisol (which is also acting on MRs) to avoid non-
speciﬁc side effects.Table 8A
Human trials: glucocorticoids combined with CBT.
Disorder Study design Outc
Social phobia Cortisone or placebo administered orally 1 h before a
socio-evaluative stressor
Redu
Spider phobia Cortisol or placebo administered orally 1 h before
exposure to a spider photograph in 6 sessions
distributed over 2 weeks
Prog
Redu
sessi
Spider phobia Cortisol or placebo administered orally 1 h before 2
exposure therapy sessions
Follow-up after 1 month
Sign
Fear
Cort
durin
Acrophobia Cortisol or placebo was administered orally 1 h before
virtual reality exposure to heights
Follow-up after 1 month
Grea
acro
follo
PTSD (combat-related) Memory reactivation task followed by intravenous
administration of cortisol or saline
Follow-up after 1 month
Redu
No d
(init
PTSD 10 weekly sessions of prolonged exposure therapy,
cortisol or placebo 30min prior session 3–10
Acce
Cave4.9. Neurotrophins and miscellaneous targets
4.9.1. Fibroblast growth factor-2
Fibroblast growth factor-2 (FGF2) is amulti-functional growth factor
involved in brain development and learning-relatedmolecular signaling
cascades (reviewed in Graham & Richardson, 2011a). FGF2 signaling is
associated with glutamate-mediated synaptic plasticity (Numakawa
et al., 2002), L-type voltage gated calcium channel expression and
activation (Shitaka et al., 1996) and phosphorylation of both MAPK
(Abe & Saito, 2000) and CREB (Sung et al., 2001). FGF2 also promotes
LTP in the HPC (Terlau & Seifert, 1990). Hence, FGF2 interacts with the
molecular tools required for the formation and consolidation of extinc-
tion memories. FGF receptors are tyrosine kinase receptors expressed
widely throughout the brain, including in areas within the extinction
circuitry such as the HPC and the CeA, and FGF2 expression in the HPC
and the mPFC is induced under stress (Molteni et al., 2001), thus sug-
gesting that emotionally arousing situations requiring new learning
generate increased FGF2 signaling which supports the formation of
emotional memories.
FGF2 has been shown to cross the blood–brain barrier (Deguchi
et al., 2000) and pioneering work demonstrates that systemic adminis-
tration of FGF2 prior to or following extinction training facilitates the
consolidation of extinction memories (Graham & Richardson, 2009,
2010). Local infusion into the BLA replicates the extinction-facilitatingome (compared to placebo control group) Reference
ced self-reported fear during anticipation and exposure (Soravia et al., 2006)
ressive reduction of stimulus-induced fear
ction of fear was maintained also 2 days following
on ending (OFF-drug)
(Soravia et al., 2006)
iﬁcant decrease in phobic symptoms assessed with the
of Spiders Questionnaire
isol-treated patients reported signiﬁcantly less anxiety
g exposure to living spiders at follow-up
(Soravia et al., 2014)
ter reduction in fear of heights measured with the
phobia questionnaire both at post-treatment and at
w-up
(de Quervain et al., 2011)
ced PTSD symptomatic in cortisol-treated patients
ifferences between cortisol and saline treated patients
ial improvement was lost after 1 month)
(Suris et al., 2010)
lerated and greater decline in PTSD symptoms
at — includes only 2 patients (1 cortisol/1 placebo)
(Yehuda et al., 2010)
Table 9
Neurotrophins and miscellaneous targets in fear extinction (preclinical studies).
Neurotrophins
Drug/manipulation Extinction
learning
Extinction
retrieval
Long-term
extinction
Route Reference
FGF2 (+)# + ns sc (Graham & Richardson, 2009)
ns +1 + (Re-in) (Ren-A) sc (Graham & Richardson, 2009, 2010)
ns +1 + (Ren-A) BLA (Graham & Richardson, 2011b)
BDNF No training +**2 No effect (Re-in) IL (Peters et al., 2010); (Rosas-Vidal et al., 2014)
No training No effect2 ns PL (Rosas-Vidal et al., 2014)
7.8-Dihydroxyﬂavone (+)* No effect (+) (Re-in) ip (Andero et al., 2011)
No effect No effect* + (Ren-A) ip (Baker-Andresen et al., 2013)
Lentiviral transfected dominant negative form of TrkB No effect − ns BLA (Chhatwal et al., 2006)
BDNF KD in HPC − ns ns No drug (Heldt et al., 2007)
Val66Met BDNF SNP − ns ns No drug (Soliman et al., 2010)
BDNF +/− KO −*** −*** ns No drug (Psotta et al., 2013)
BDNF antibody − − ns IL (Rosas-Vidal et al., 2014)
No effect No effect ns PL (Rosas-Vidal et al., 2014)
BDNF KO in forebrain ns No effect# ns PL (Choi et al., 2010)
Methylene blue, nitric oxide, histamine, and LTCCs
Methylene blue ns +1 ns ip (Gonzalez-Lima & Bruchey, 2004)
ns ns +1* (Ren-A) ip (Wrubel et al., 2007)
Histamine ns +1 ns CA1 (Bonini et al., 2011)
Dimaprit (H2 ag) ns +1 ns CA1 (Bonini et al., 2011)
Ranitidine (H2 ant) ns −1 ns CA1 (Fiorenza et al., 2012)
ns −1 ns BLA (Fiorenza et al., 2012)
ns −1 ns PFC (Fiorenza et al., 2012)
SKF9188 (histamine methyl-transferase inhibitor) ns +1 ns CA1 (Fiorenza et al., 2012)
ns +1 ns BLA (Fiorenza et al., 2012)
ns +1 ns PFC (Fiorenza et al., 2012)
L-NAME (nNOS inhibitor)4 − − ns ip (Luo et al., 2014)
CamKII-Cre Cav1.2 KO No effect ns ns No drug (McKinney et al., 2008)
Cav1.3 KO No effect ns ns No drug (Busquet et al., 2008)
No effect ns ns No drug (McKinney & Murphy, 2006)
Nifedipine (LTCC ant) − ns ns ip (Cain et al., 2002)
No effect ns ns icv (Busquet et al., 2008)
No effect − ns BLA (Davis & Bauer, 2012)
ns −1 ns HPC (de Carvalho Myskiw et al., 2014)
Verapamil (VGCC ant) No effect − ns BLA (Davis & Bauer, 2012)
1 Drug administration following extinction training; 2 drug administration 24 h prior extinction retrieval 3 drug administration 30min prior extinction retrieval 4 ABA scheme, 40mg/kg.
* Facilitates rescue of impaired fear extinction; ** facilitates extinction of remotememories, *** only in older animals (7months), younger ones (2months) are not affected, # reduced fear
expression at the beginning of extinction training.
+, improved;−, impaired; (+) or (−), only minor effects; ip, intraperitoneal injection; sc, subcutanous injection; icv, intracerebroventricular injection; ns, not studied; HPC, intra-
hippocampal administration; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; PL, prelimbic cortex; CA1, cornu ammonis 1; Ren-A, Fear renewal in conditioning con-
text; SR, spontaneous recovery; Re-in, reinstatement; ag, agonist; ant, antagonist, KO, knock-out;
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this neurotrophin's action (Graham&Richardson, 2011b). Of signiﬁcant
importance, is the fact that FGF2-augmented extinction has been associ-
ated with enhanced protection against return of fear phenomena in-
cluding renewal and reinstatement [(Graham & Richardson, 2009,
2010, 2011b), see Table 9 for details] making it an interesting candidate
for future clinical applications. Clinical studies investigating the poten-
tial of FGF2 in CBT could be implemented in the near future as human
trials investigating FGF2 for angiogenesis have already shown some
drugs to be safe (Laham et al., 2000).
4.9.2. Brain-derived neurotrophic factor
Brain-derived neurotrophic factor (BDNF) is the most abundant
neurotrophin in the CNS and a key player in synaptic plasticity
(reviewed in Andero & Ressler, 2012). BDNF binds with high afﬁnity
to the tropomyosin-related kinase B (TrkB) receptor andwith low afﬁn-
ity to the p75NTR, a receptor for multiple neurotrophins (Reichardt,
2006). BDNF and TrkB are present in the HPC, AMY, PFC and the hypo-
thalamus, and are integral components of fear extinction mechanisms
as blunted activity of BDNF-TrkB signaling is associated with deﬁcient
extinction retrieval in rats (Kabir et al., 2013). Conversely, increased
levels of BDNF mRNA are observed in the BLA (Chhatwal et al., 2006),
mPFC (Bredy et al., 2007) following successful fear extinction. The po-
tential utility of BDNF-TrkB signaling as cognitive enhancing target is
underscored by the ﬁndings that stimulating TrkB signaling byadministering the TrkB agonist 7,8-dihydroxyﬂavone (DHF) facilitates
LTP induction in the AMY (Li et al., 2011) and can augment fear extinc-
tion (Peters et al., 2010; Rosas-Vidal et al., 2014).
Haploinsufﬁciency of BDNF leads to deﬁcits in extinction learning
and retrieval (Psotta et al., 2013), while inhibition of the BDNF-evoked
signaling cascade via transfection of a dominant negative form of the
TrkB receptor speciﬁcally disrupts extinction consolidation in a fear po-
tentiated startle paradigm (Chhatwal et al., 2006). Conversely, systemic
injection of the TrkB agonist DHF promoted extinction in a stress model
of impaired fear extinction and protected against the reinstatement
of fear (Andero et al., 2011) (for an overview, see Table 9). In mice and
humans, a single nucleotide polymorphism (SNP) in the BDNF gene
(Val66Met), causing inefﬁcient BDNF trafﬁcking and reduced activity-
dependent BDNF secretion, is associated with poor extinction (Table 9)
and abnormal fronto-AMY activity (Soliman et al., 2010). Moreover,
human carriers of the BDNF Val66Met SNP show reduced responsivity
to exposure-based therapies [reviewed in (McGuire et al., 2014)],
underscoring the potential role of BDNF in deﬁcient fear extinction.
Studies aimed at identifying the site of BDNF-induced effects on ex-
tinction showed that deletion of BDNF in theHPC, but not in the PL (Choi
et al., 2010), impairs fear extinction learning (Heldt et al., 2007). In ad-
dition, injection of BDNF antibodies (anti-BDNF) in the IL prior to extinc-
tion training disrupts acquisition and retrieval of extinction memories
while anti-BDNF infusions in the PL cortex do not affect extinction
(Rosas-Vidal et al., 2014) (Table 9). These ﬁndings indicate that BDNF
175N. Singewald et al. / Pharmacology & Therapeutics 149 (2015) 150–190signaling in the HPC and the IL support the formation andmaintenance
of fear extinction memories. In fact, local BDNF injections in the IL pro-
duced fear inhibition for recent aswell as remote fearmemories even in
the absence of extinction training (Peters et al., 2010; Rosas-Vidal et al.,
2014). Given the possibility that BDNF infusions into the IL could rein-
state fear by using the aforementioned extinction-independent para-
digm (Peters et al., 2010), BDNF seems to induce signaling cascades
crucial for the formation of extinction memories rather than decreasing
the stability of the original fear memory. Overall these effects are
consistent with a model in which the effects of BDNF are brain-region
dependent, and BDNF appears to enhance synaptic plasticity of
the most robust form of learning occurring in a time- and region-
dependent manner.
Various targets described in this reviewmaymediate their effects on
extinction via interactions with BDNF. For example, chronic treatment
with the SSRI ﬂuoxetine (Section 4.1: Serotonergic system) facilitates ex-
tinction and enhances BDNF levels in the AMY and the HPC (Karpova
et al., 2011). Valproate, an extinction-promoting inhibitor of histone
deacetylation (see Section 4.10: Epigenetics), increases BDNF mRNA in
the mPFC (Bredy et al., 2007). Furthermore, TrkB activation triggers the
release of eCBs (Lemtiri-Chlieh & Levine, 2010) and increases the expres-
sion of CB1 receptors (Maison et al., 2009), hence potentially contributing
to extinction memory formation (see Section 4.6: Cannabinoids). Finally,
BDNF Met66 knock-in mice exhibit dysfunctional NMDA receptor-
dependent synaptic plasticity in addition to reduced extinction
acquisition (Ninan et al., 2010) that is rescued by systemic administra-
tion of D-cycloserine (Yu et al., 2009), underscoring an additional strong
interaction between BDNF and the glutamatergic system [see (Andero
& Ressler, 2012) for more details].
These ﬁndings suggest that BDNF signaling may be an important
common signaling pathway for various systems involved in extinction.
Although poor blood–brain-barrier permeability (Wu, 2005) limits the
therapeutic potential of BDNF itself, TrkB receptor agonists such as
DHF (see above) or LM22A-4 (Massa et al., 2010) may hold promise
for CBT-adjunctive therapy in anxiety.4.9.3. Nitric oxide and methylene blue
Nitric oxide (NO) signaling has received considerable attention in
terms of its effect on fear learning and has been shown, for example,
to be implicated in the formation of LTP at thalamic input synapses in
the LA (Shin et al., 2013). One recent study did demonstrate that reduc-
ingNO signaling via inhibition of nitric oxide synthase (e.g. via L-NAME)
impairs extinction learning and retrieval (Luo et al., 2014), indicating
that NO signaling may also be involved in the formation and mainte-
nance of fear extinction memories.
More work has been done on the brain penetrant methylene blue,
which is an inhibitor of NO synthase, aswell as a centralmonoamineox-
idase (MAO) inhibitor and a cerebral metabolic enhancer (reviewed in
Rojas et al., 2012). A contribution of nitric oxide to the behavioral effects
of this and related compounds was suggested in relation to their ob-
served antidepressant-like activity (Harvey et al., 2010).
In rodents, subchronic administration of methylene blue facilitates
extinction retrieval (Gonzalez-Lima & Bruchey, 2004) (Table 9) and in-
creases metabolic activity in the IL subdivision of the mPFC. Methylene
blue administration also rendered extinctionmemories resistant to fear
renewal when administered following extinction training in a learned
helplessness model exhibiting impaired extinction (Wrubel et al.,
2007).). Because methylene blue is used to treat metemoglobinemia
and has a well-described safety proﬁle (Ohlow & Moosmann, 2011),
these preclinical data could be quickly moved forward to clinical inves-
tigations. Indeed, the ﬁrst clinical study has recently reported that
methylene blue treatment during CBT led to greater fear inhibition
that was persistent for at least one month [(Telch et al., 2014) see
Table 9A for details]. However, similar to the proﬁle of DCS discussed
earlier, only those patients capable of showing some extinctionbeneﬁted from themethylene blue treatment. A clinical trial investigat-
ing the potential of methylene blue in PTSD (NCT01188694) is now
under way.4.9.4. Histamine
The tuberomammillary nucleus is the main source of histamine in
the brain. Histaminergic projections innervate main monoaminergic
nuclei, such as raphe nuclei and locus coeruleus (Lee et al., 2005), as
well as extinction relevant brain areas, including the AMY, mPFC and
hippocampus (Kohler et al., 1985). To date, 4 histamine receptor sub-
types (H1–4) have been identiﬁed — H1–3 are expressed in the CNS,
while H4 is involved in chemotactic processes of the immune system.
Local histamine infusions into the CA1 region of the HPC have been as-
sociated with improved extinction consolidation (Bonini et al., 2011).
This effect is H2 receptor mediated, since the H2 agonist dimaprit
facilitates extinction consolidation while the histamine H2 antagonist
ranitidine impairs it, when injected into the CA1, BLA or IL following ex-
tinction training (Bonini et al., 2011; Fiorenza et al., 2012). Furthermore,
both histamine and the H2 agonist dimaprit facilitate extinction-
induced phosphorylation of Erk1, suggesting a possible molecular path-
way mediating the augmenting effects of H2 receptor agonism on ex-
tinction consolidation (Bonini et al., 2011). However, although the H1
antagonist hydroxyzine has been used in some anxiety therapies
(Guaiana et al., 2010), the potential clinical use of histaminergic drugs
in particular targeting the H2 receptor for CBT augmentation has not
been investigated.4.9.5. Voltage gated calcium channels
Voltage-gated calcium channels (VGCCs) are classiﬁed into L-, P/Q-,
R-, N- and T-type VGCCs (for a review see Catterall et al., 2005). A rise in
intracellular calcium via NMDA receptor or VGCC activation initiates
various secondmessenger signaling cascades that play a role in LTP for-
mation. Due to their neuronal expression as well as their association
with gene transcription the L-type calcium channels (LTCCs) Cav1.2
and Cav1.3 (Striessnig et al., 2006, 2014) have attracted most attention
in the fear conditioning ﬁeld.
Early studies have shown that systemic injections of LTCC blockers,
e.g. nifedipine (that inhibits Cav1.2 and Cav1.3 channels), impair fear
extinction acquisition (Cain et al., 2002). However, whole‐brain gene
knockout of Cav1.3 channels (Busquet et al., 2008; McKinney &
Murphy, 2006) as well as conditional knockout of Cav1.2 on CaMKII-
expressing principal neurons (McKinney et al., 2008) failed to replicate
deleterious effects of LTCC blockers on extinction training. Pre-training
icv infusion of nifedipine has revealed no effect on extinction learning
(Busquet et al., 2008), suggesting that the extinction-impairing effects
of systemic nifedipine may be due to peripheral actions (Waltereit
et al., 2008).
However, pre-training intra-BLA or intra-HPC infusion of nifedipine,
or of another LTCC blocker, verapamil, impairs extinction retrieval 24h
later (Davis & Bauer, 2012; de Carvalho Myskiw et al., 2014), indicating
a role for LTCCs within these regions in the consolidation of extinction.
This effect could be related to Cav1.3 mediation of synaptic plasticity
and neuronal excitability in the AMY (McKinney et al., 2009) or to
altered neuronal ﬁring in the CA1 region of the HPC (Gamelli et al.,
2011). However, the effect on extinction consolidation of selective
Cav1.3 activation has not been assessed so far.
While activation of Cav1.2 channels produces severe neurological ef-
fects and germline gain of Cav1.3 function is deleterious (Scholl et al.,
2013), selective Cav1.3 activation in adulthood has been shown to be
tolerated at least in mice (Hetzenauer et al., 2006; Sinnegger-Brauns
et al., 2004). Hence, short term use of such compounds, as would typi-
cally be required in combination with exposure therapy, should be pos-
sible. Taken together, these preclinical ﬁndings raise the prospect of
targeting LTCCs, and Cav1.3 in particular, for the treatment of anxiety.
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The formation of extinctionmemories requires an intricate regulato-
ry network of signal transduction, gene transcription and translation.
A key step in this process involves the coordinated transcription of spe-
ciﬁc genes coding for learning-associated transcription factors, synaptic
plasticity factors, neurotransmitter receptors, cytoskeletal proteins
and other cellular substrates [reviewed in (Monti, 2013; Whittle &
Singewald, 2014)]. Gene transcription is in turn tightly controlled by
epigenetic mechanisms (Callinan & Feinberg, 2006). Epigenetic mecha-
nisms regulate the accessibility of deoxyribonucleic acid (DNA) to
transcription-initiatingmachinery via certainmolecular events including
histone tail post-translational modiﬁcations and DNA methylation. In
this section we will focus on histone acetylation and DNA methylation,
with emphasis on their dynamic interactions within the chromatin envi-
ronment that orchestrate the regulation of genes at the molecular level,
and review accumulating evidence that modulation of extinction-
relevant receptors at the synapse can initiate epigenetic programswithin
the nucleus and modulate extinction in a persistent and context-
independent manner. We will also review data showing that drugs
targeting epigenetic mechanisms may serve to strengthen extinction.
4.10.1. Histone modiﬁcations
To date, a main focus of research is on understanding the interaction
between histonemodiﬁcations and the strengthening of fear extinction
memories. In eukaryotic cells, DNA is organized in a highly conserved
structural polymer, termed chromatin. The basic building block of chro-
matin is the nucleosome, which consists of 146 base pairs (bp) of DNA
wrapped around an octamer consisting of (dimers of) core histone pro-
teins (H2A, H2B, H3, and H4) held together by a H1 linker protein
(Kornberg& Lorch, 1999). Histones contain a globular domainwith a co-
valently modiﬁable N-terminal tail consisting of lysine and/or arginine
residues. Histone modiﬁcations constitute a signal that is read alone
or, in combination with other modiﬁcations and interactions with
neighboring histones — a ‘histone code’ (Kouzarides, 2007). At least 9
different posttranslational modiﬁcations, including acetylation, phos-
phorylation, methylation, biotinylation, SUMOylation, ADP ribosylation,
and ubiquitination, inﬂuence chromatin condensation, resulting in gene
transcription by coordinating protein and enzyme complex accessibility
to DNA (Ruthenburg et al., 2007). Here, we focus primarily on the most
well-studied histone modiﬁcation in extinction— acetylation of histone
proteins.
Histone acetylation on lysine (K) residues leads to transcriptional
activation by neutralizing the positive charge of the K ε-amino group
of histone tails, which in-turn relaxes chromatin by reducing the elec-
trostatic bonding of histone with negatively charged DNA (Grayson
et al., 2010). The enzymes involved in regulating this process are 1) his-
tone acetyltransferases (HATs), also known as lysine acetyltransferases
(KATs) (Allis et al., 2007) or ‘writers’ (Monti, 2013) and 2) histone
deacetylases (HDACs), also known as lysine deacetylases (KDACs)
(Choudhary et al., 2009) or ‘erasers’ (Monti, 2013). HATs acetylate K
residues to promote gene transcription, whereas HDACs, which are
present in co-repressor complexes, remove K residues to impair gene
transcription (see Fig. 9.) [for greater detail, see (Fischer et al., 2010)].
There is some evidence that extinction is associated with alterations
in HAT activity and that drugs increasing HAT activity could constitute a
novel approach to augmenting extinction (Fig. 9.). Following extinction,
there is increased expression of the HAT p300/CBP-associated factor
(PCAF) in the rodent IL, and intra-IL infusion of the PCAF activator,
SPV106, facilitates extinction and protects against fear renewal (Wei
et al., 2012). However, inhibiting, rather than activating, the activity of
another HAT, p300, in the IL also strengthens extinction (Marek et al.,
2011). One possible explanation of this ﬁnding is that rather than
strengthening extinction, p300 may bolster fear memory
reconsolidation via transcription of genes including nuclear factor κB
(NF-κB) (Furia et al., 2002; Perkins et al., 1997) and yin-yang 1 (YY1)(Yao et al., 2001), known to be involved in reconsolidation (Gao et al.,
2010; Lubin & Sweatt, 2007). These two studies that demonstrate how
targeting HATs affects fear in different ways indicate the need for addi-
tional work to determine the optimal approach to facilitate extinction
with HAT modulators.
There is an increasing amount of evidence to suggest that histone
acetylation is an important mechanism promoting successful fear ex-
tinction (reviewed in (Whittle & Singewald, 2014)] (Fig. 9.). An impor-
tant early study found that histone extinction is associated with
increased acetylation of histone H4 in the promoter region of bdnf
exon IV (Bredy et al., 2007). Subsequent work showed that administra-
tion of various HDAC inhibitors including TSA (trichostatin A), sodium
butyrate, entinostat (MS-275), vorinostat (SAHA, suberoylanilide
hydroxamic acid), VPA (valproic acid) and Cl-944 can augment fear ex-
tinction (Table 10). The potential clinical utility of using HDAC inhibitors
has been further strengthened by showing that Cl-944, MS-275 and
SAHA rescue extinction deﬁcits in various rodent models (Graff et al.,
2014; Hait et al., 2014; Matsumoto et al., 2013; Whittle et al., 2013)
(see Table 10).
An additional attribute of HDAC inhibitors is their ability to
extinguish remote (aged) fear memories that are normally resistant
to extinction. Extinction of recent fear memories (1 day after condi-
tioning), using a memory update-consolidation paradigm, increases
HDAC2 nitrosylation (Graff et al., 2014), which facilitates the dissoci-
ation of HDAC2 from chromatin (Nott et al., 2008), leading to histone
hyper-acetylation and HPC expression of extinction-relevant genes
including c-Fos. By contrast, nitrosylation of HDAC2 and c-Fos ex-
pression do not increase after extinction training of remote (1
month post conditioning) fear memories (Graff et al., 2014)
(Fig. 9.). Systemic administration of the HDAC inhibitor Cl-994 was
able to rescue remote extinction and the associated gene expression
deﬁcits. Rescue of impaired remote extinction has been observed
with dietary zinc restriction, which inhibits HDAC in addition to
affecting other systems (Holmes & Singewald, 2013; Whittle et al.,
2010). Collectively, these two studies support the potential clinical
utility of HDAC inhibitors as adjuncts to CBT treatment of fearful
memories that started long after the exposure to trauma.
Further supporting a role of HDAC activity in the modulation of fear
extinction mechanisms is the observation that reduced HDAC activity is
associated with improvements in fear extinction (Hait et al., 2014). At
present 18 different mammalian HDAC isoforms have been identiﬁed,
and they are divided into four classes (Classes I–IV). Targeting individual
HDAC isoforms is an important aim of drug development (Grayson et al.,
2010). Themajority of currently available HDAC inhibitors target multi-
ple isoforms of the HDAC family (e.g. classes I, II, and IV), while some of
the HDAC inhibitors that have proved to be successful in augmenting
fear extinction (Table 10) exhibit preferential selectivity towards
class-I HDACs (encompassing HDAC1, HDAC2, HDAC3 and HDAC8)
(Haggarty & Tsai, 2011).
Studies using gene knockdown or over-expression suggest that
targeting speciﬁc HDAC isoforms could indeed be a promising approach
to modulating extinction [reviewed in (Whittle & Singewald, 2014)].
This is exempliﬁed by the recent ﬁnding that gene silencing of HDAC2,
but not HDAC1, in forebrain neurons promotes extinction (Morris
et al., 2013). However, the effect of speciﬁcally inhibiting other HDAC
isoforms, including HDAC3 [recently shown to facilitate the extinction
of drug-seekingmemories (Malvaez et al., 2013)], remains to be tested.
It is likely that the extinction-facilitating effects of HDAC inhibitors
are due to activation of extinction-related gene transcription programs.
The HDAC inhibitors SAHA and VPA increase, respectively histone acet-
ylation in the promoter region of grin2b (NMDA receptor subunit 2B)
(Fujita et al., 2012), and histone H4 acetylation in promoter IV of bdnf,
leading to increased BDNF exon IV mRNA expression (Bredy et al.,
2007). In addition, the HDAC inhibitor Cl-994 increases histoneH3 acet-
ylation in the promoter region of plasticity associated genes including
igf2, adcy6, c-Fos, npas4, and arc (Graff et al., 2014). Indeed, a range of
Fig. 9. Schematic representation depicting the epigenetic regulation of fear extinction. DNA methylation is associated with suppression of gene transcription. The precise molecular pro-
cesses through which this occurs are complex. In brief, methylation of cytosines at CpG dinucleotides recruits methyl-DNA binding proteins, at speciﬁc sites in the genome. Proteins that
bind tomethylated DNA, includingmethyl CpG-binding protein 2 (MeCP2) andmethyl CpG-binding domain protein 1 (MBD1), have both amethyl-DNA binding domain and a transcrip-
tion-regulatory domain. The transcription-regulatory domain recruits adapter/scaffolding proteins, which in turn recruit HDACs, includingHDAC2, to repress gene transcription [reviewed
in (Sweatt, 2009). Following extinction related neuronal activity a number of molecular mechanisms are invoked, ultimately leading to facilitated histone acetylation and subsequent en-
hancement of gene transcription. These mechanisms include enhancement of HAT activity, such as PCAF (see text) and a reduction in HDAC activity by mechanisms which include
nitrosylation (NO) of HDACs, including HDAC2, which facilitates dissociation of HDAC from the chromatin. Moreover, enhanced histone acetylation may also be mediated by the conver-
sion of DNA demethylation which is mediated by the Tet family of methylsytosine dioxygenases. Emerging pharmaceutical evidence is showing that HDAC inhibitors can facilitate gene
transcription by enhancing histone acetylation in the promoter region of extinction-relevant genes (see text).
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extinction, induce transcription of relevant genes via enhancement of
histone acetylation, including histone H3 acetylation in the promoter
region of bdnf, camk2a, creb and the NMDA receptor subunit genes
grin2a and grin2b (Shibasaki et al., 2011; Tian et al., 2009, 2010;Table 10
Studies showing that HDAC inhibitors augment exposure-based fear extinction and rescue ext
Drug/manipulat Extinction training Extinction retr
HDAC1 KO (HPC) ns −#
HDAC2 KO in forebrain CamKII neurons ns + *#
Vorinostat/SAHA ns +
ns + **
ns + **
TSA (trichostatin A) ns + *
Sodium butyrate − +
ns +
ns +
Valproic acid − + *
+ *
+ ** + **
MS-275 (entinostat) − + **
Cl-994 ns + ***
FTY720 (ﬁngolimod) − + **
* Partial extinction training: reduction of fear during the extinction training sessionwas not to p
memories combined with memory re-consolidation update paradigm; # extinction protocol b
+, Improved;−, impaired; ip, intraperitoneal injection; ns, not studied;HPC, intra-hippocampa
novel context; SR, spontaneous recovery; # reduced freezing levels at the beginning of extinctTsankova et al., 2006). Concerning a possible convergent downstream
mechanism for these effects, serotonin via activation of PKA signaling
pathways (Guan et al., 2002), L-type calcium channel activation
(Dolmetsch et al., 2001) and BDNF/TrkB activation (Correa et al.,
2012) all activate the MAPK/ERK signaling pathway, which is crucialinction learning deﬁcits.
ieval Longterm extinction Route Reference
ns No drug (Bahari-Javan et al., 2012)
ns No drug (Morris et al., 2013)
ns ip (Fujita et al., 2012)
ns ip (Matsumoto et al., 2013)
ns ip (Hait et al., 2014)
ns ip, HPC (Lattal et al., 2007)
+ (SR) ip, HPC (Stafford et al., 2012)
ns ip (Itzhak et al., 2012)
ns ip, HPC (Lattal et al., 2007)
ns ip (Bredy et al., 2007)
+ (Ren-A) ip (Bredy & Barad, 2008)
+ (SR, Ren-N) ip (Whittle et al., 2013)
+ (SR, Ren-N) ip (Whittle et al., 2013)
+ (SR) ip (Graff et al., 2014)
ns ip (Hait et al., 2014)
re-conditioning levels, ** facilitates rescue of impaired fear extinction; *** facilitate remote
ased on a re-consolidation/update paradigm
l administration; Ren-A, Fear renewal in the conditioning context; Ren-N, Fear renewal in a
ion training
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naling to the nucleus could increase histone acetylation by enhancing
activity of the HAT CREB-binding protein (CBP) (Chrivia et al., 1993).
4.10.2. DNA methylation
DNA methylation is a crucial mechanism for controlling chromatin
remodeling in the adult mammalian nervous system (Levenson et al.,
2006; Nelson et al., 2008) and can occur at multiple sites within a
gene. DNA methylation is a direct chemical modiﬁcation of a cytosine
side-chain that adds a methyl (–CH3) group through a covalent bond,
catalyzed by a class of enzymes known as DNA methyltransferases
(DNMTs) (Okano et al., 1998). The DNMTs transfermethyl groups to cy-
tosine residueswithin a continuous stretch of DNA, speciﬁcally at the 5′-
position of the pyrimidine ring (5-methylcytosine) (Chen et al., 1991).
Not all cytosines can be methylated; typically, cytosines are followed
by a guanine in order to be methylated (Day & Sweatt, 2011) (Fig. 9.).
However, given the recent ﬁnding that methylation can occur outside
CpG islands and in CpH (where H= adenine/cytosine/thymine) islands
and that these CpH islands can repress (Guo et al., 2014) substantially
expands and adds further complexity to how methylation can regulate
gene transcription in the central nervous system. Furthermore, this
ﬁnding raises the open question of whether CpH methylation is a mo-
lecular mechanism regulating fear extinction.
In a pioneering study, linking DNA methylation and extinction,
extinction-resistant female mice were found to exhibit increased DNA
methylation of Bdnf exon IV and a concomitant decrease in BDNF
mRNA expression in the PFC (Baker-Andresen et al., 2013). The fact
that DNA methylation is reversible suggests that enhancement of gene
transcription by DNA demethylation could represent a novel mecha-
nism for strengthening extinction that has the potential to be pharma-
ceutically exploited. Along these lines, the ten-eleven translocation
(Tet) family of methylcytosine dioxygenases, which includes Tet1,
Tet2, and Tet3 enzymes, catalyze oxidation of 5-methylcytosine to 5-
hydroxymethylcytosine and thereby promotes DNA demethylation
(Ito et al., 2011; Tahiliani et al., 2009).
Two recent studies demonstrate the importance of these Tet en-
zymes in extinction. Extinction leads to a genome-wide redistribution
of 5-hydroxymethylcytosine and Tet3 occupancy to extinction-
relevant genes including the GABAA clustering protein, gephyrin (see
Section 4.5: γ-aminobutyric acid (GABA)), and to enhanced gephyrin
mRNA expression in the IL (Li et al., 2014). Furthermore, gene knock-
down of Tet1 impairs extinction (Rudenko et al., 2013). While agents
targeting Tet enzymes are not currently available, these emerging pre-
clinical ﬁndings may provide the impetus to develop such compounds.
4.10.3. Non-coding RNA
In addition to histone modiﬁcations and DNAmethylation, gene ex-
pression is also regulated by non-coding RNAs including micro-RNAs
(miRNAs) (Spadaro & Bredy, 2012). miRNAs represent classes of non-
coding RNAs that mediate post-transcriptional regulation of gene ex-
pression, including genes associated with synaptic plasticity, learning
and memory (Barry, 2014). Although miRNAs are usually associated
with preventing mRNA translation and thereby with suppressing new
protein synthesis, a speciﬁc miRNA was recently shown to augment
fear extinction. Fear extinction enhanced the expression of miR-128b
in the IL associated with down-regulation of plasticity-related genes in-
cluding creb1 and sp1 in tandem with inhibition of the original fear
memory (Lin et al., 2011). Clearly, further clariﬁcation of the role of
non-codingRNAs during fear extinction iswarranted, including through
the development of tools by which speciﬁc non-coding RNAs can be
modulated.
5. Discussion and ﬁnal conclusions
In this reviewwe aimed to summarize (druggable) systems involved
in fear extinction and how pharmacological compounds have beenutilized to augment fear extinction in preclinical and small-scale clinical
studies. It is anticipated that these ﬁndings are paving the way for clin-
ical use of such approaches given that extinction training is procedurally
similar to exposure-based psychotherapy and the underlying fear/ex-
tinction circuitries and molecular mechanisms are well conserved
across species (Milad & Quirk, 2012). As mentioned in the introduction,
the main problems with current exposure-based CBT treatment of fear,
anxiety and trauma-related disorders are that a signiﬁcant proportion of
patients either: 1) have difﬁculties bearing the demanding and
exhaustingprocess of this therapy, 2) do not, or not sufﬁciently, respond
to the therapy — failing to substantially reduce their fear response, or
3) responds initially, but suffer from return of fear phenomena hamper-
ing remission and full recovery. In this reviewwe summarize the phar-
macological approaches that have been investigated and utilized to
improve these shortcomings. Initial attempts to combine exposure-
based CBT with pharmacotherapy included benzodiazepines that
dampened anxiety but also reduced the learning effects of this proce-
dure hence provoking return of fear symptoms upon discontinuation
(Hofmann, 2012; Otto et al., 2002, 2010a). A complicating issue is the
observation that the interoceptive state induced by such anxiolytics
can formpart of a “context”, and consequentlymay promote fear in sub-
sequent testing in an “off drug state”, leading to state-dependent learn-
ing due to a change in interoceptive context (Maren et al., 2013).
However, there is evidence that targeting novel anxiolytic systems
such as theNPS systemor ﬁbroblast growth factor-2may elicit acute an-
xiolytic effects without producing sedation, state-dependency and/or
interference with the formation of extinction memories. These ﬁndings
are particularly exciting as they are beginning to address one of the im-
portant problems associated with CBT (i.e. intolerability to CBT expo-
sure). However, more research is necessary to prove the utility of such
approaches. As well as improving tolerability to exposure, improve-
ments concerning onset, magnitude and duration of the therapeutic
effect of exposure-based CBT are also in themain focus of drug develop-
ment in this ﬁeld. As outlined in this review, the augmentation of fear
extinction/exposure therapy with a range of different drugs acting as
cognitive enhancers to strengthen extinction memories represents an
important approach to enhancing therapy efﬁcacy. This has been
made possible by revealing the neurochemical/neurobiological re-
sponses within the neural circuitry whose activity is required for fear
extinction and, by extension, to rescue fear extinction deﬁcits.
Considerable progress has been made in deﬁning the neural basis of
fear extinction and fear extinction deﬁcits (for recent reviews see (Milad
&Quirk, 2012; Holmes & Singewald, 2013; Parsons & Ressler, 2013). The
steadily growing knowledge concerning where and how fear extinction
is processed and how it can be pharmacologically augmented is an
essential platform from which to identify promising candidates for
extinction-promoting therapeutics. Indeed, by successfully translating
ﬁndings from animal models, progress has been made in enhancing
the outcomes of exposure-based CBT using compounds such as DCS, yo-
himbine and glucocorticoids as cognitive enhancers in the treatment of
patientswith anxiety disorders, PTSD andOCD (Hofmann& Smits, 2008;
McGuire et al., 2014; Norberg et al., 2008).
As outlined in this review, an impressive number of additional ex-
tinction augmenting drugs, acting on a wide variety of pharmacological
targets, have indeed been identiﬁed. Data arising from the use of animal
models displaying deﬁcient fear extinction, reﬂecting patients resistant
to exposure therapy, indicate that different neurotransmitter/neurobio-
logical signaling pathways are involved in different temporal phases of
extinction. Hence, it is likely that different pharmacological approaches
will be required to either induce fear reductions during extinction train-
ing or rescue/boost the consolidation of fear extinction (reviewed in
(Holmes & Singewald, 2013). The important ﬁnding that within-
session fear reduction/habituation favors drug-augmented extinction
rather than facilitating reconsolidation of existing fear memories
(Graham et al., 2011; Merlo et al., 2014) has also been demonstrated
in clinical trials using DCS ((Hofmann, 2014) and yohimbine (Smits
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modulate the activity of diverse neurotransmitter/neurobiological sys-
tems seem to be an important option to pursue, in particular for individ-
uals with severe extinction deﬁcit/resistance to exposure therapy.
Interestingly, in the much more well established medical ﬁelds of
infectious disease, hypertension, oncology, and similar areas, targeting
multiple differentmechanisms of action is also the norm, not the excep-
tion and it is also considered promising in other ﬁelds of psychiatry
(Millan, 2014).
One of the most important aspects of extinction-promoting drugs is
their ability to bolster extinction by enhancingmemory consolidation. It
is likely that this extinction enhancement occurs via the enhancement
of cortico-AMY synaptic plasticity through multiple mechanisms
(reviewed in (Myers & Davis, 2007; Sierra-Mercado et al., 2011; Orsini
& Maren, 2012; Duvarci & Pare, 2014), ultimately providing lasting ef-
fects and better protection from return of fear phenomena. If translated
into clinical use, these effects would support sustained symptom
remission and recovery. Some of the drug targets outlined in this review
[e.g. epigenetic targets including histone modiﬁcation, BDNF and
facilitated dopaminergic and ﬁbroblast-growth-factor-2 signaling) and
also cholinergic targets — see (Zelikowsky et al., 2013)] seem to be
promising in this respect, as they promote long-term and context-
independent fear inhibition when combined with fear extinction.
Context-independent extinction learning (extinction generalization)
offering enhanced protection against fear return phenomena such as
renewal, may be supported not only by targeting speciﬁc pharmacolog-
ical mechanisms, but also by behavioral approaches (see below).
Fortunately, some of the promising substances in that respect are ap-
proved for human use (e.g. Valproate, L-DOPA, FGF2) and thus, their
extinction-augmenting capacity could be immediately examined in
anxiety and trauma-focused clinical trials. Although some of the
discussed agents may share important common downstream signaling
pathways, it seems clear that there are a number of different pharmaco-
logical pathways to access the circuits that underlie fear extinction
learning and memory (see Fig. 3), which will enable even more
speciﬁc targeting of the essential extinction-promoting mechanisms in
the future.
Despite this clear progress there remain major challenges for the
development of medications to improve the effectiveness of
exposure-based therapies, including challenges related to the design
of safe, brain-penetrant molecules with limited adverse side-effects.
Individual differences in treatment tolerability and efﬁcacy, caused
by genetic variation, and prior medication history are further com-
plicating concerns. For example, the careful dissection of the brain
regions mediating fear extinction including the AMY, PFC, HPC and
other regions has also shown that some systems can promote both
extinction-facilitating and extinction-impairing effects depending
on the brain area/cellular substrate they are acting on. An example
is the β-adrenoceptor, blockade of which interferes with extinction
when restricted to the IL, but promotes extinction when the BLA is
targeted — hence it is difﬁcult to predict the net effect of medicating
a patient with a β-adrenoceptor blocker or agonist during exposure
therapy. The targeting of speciﬁc intracellular signaling cascades
might be a solution for future, more selective approaches in this
direction. Research in the last few years has revealed that the speciﬁc
ligands can bias the signal output of G-protein coupled receptors by
stabilizing the receptor structure in a distinct way to the natural
ligand. By providing a means to produce functional selectivity,
biased agonists and antagonists may be utilized to activate preferen-
tial, even unnatural, signaling cascades mediating the therapeutical-
ly favored downstream biological consequences [for a recent review
see (Luttrell, 2014)].
Another important aspect for future clinical implementation of
drug-induced facilitation of exposure therapy outcome concerns the
time course of drug administration. While current drug treatment for
anxiety and trauma-related disorders involves mainly chronictreatment (e.g. with SSRIs, SNRIs, TCA, MAOI) the compounds discussed
in this review are (with the exception of antidepressants) recommend-
ed to be applied acutely in combination with psychotherapeutic inter-
ventions for a limited number of exposure trials. This strategy includes
several advantages: First, chronic application of drugs can induce very
different biological effects from those observed with acute administra-
tion. It is extremely challenging to predict how and at which stage
(recall of fear memory, learning, reconsolidation, consolidation, retrieval
of extinction memory) chronically applied drugs will enhance/interfere
with fear extinction. For example, it is likely that facilitation of extinction
and disruption of fear reconsolidation, both leading to fear reduction,
depend on opposingmolecular processes, such that chronic administra-
tion of the same drug may lead to very different therapeutic outcomes
depending on which process (i.e. extinction or reconsolidation) it en-
hances (Graham et al., 2011). Second, acute administration implies a
reduced side effect potential. One example is the addiction potential
of some of the compounds currently examined for extinction augmen-
tation (e.g. MDMA). Indeed, ﬁrst clinical trials reported that none of
the involved patients developed a substance abuse problem when
MDMA was administered acutely to assist psychotherapy (Mithoefer
et al., 2013).
In addition to pharmacological parameters, the efﬁcacy and duration
of exposure therapy in humans may also depend (as shown in animal
studies) on manipulation of speciﬁc behavioral extinction training pa-
rameters [see also e.g. (de Carvalho Myskiw et al., 2014; Schiller et al.,
2012)] such as providing sufﬁcient extinction training, enhancing the
number of contexts for such training, trial spacing, and other ap-
proaches (reviewed in Herry et al., 2010; Fitzgerald et al., 2014a).
It will be an important future line of research to test the optimal combi-
nations between such behavioral interventions and the outlined phar-
macological approaches in order to maximize treatment outcome. It is
also important to note that thought needs to be given to a variety of fac-
tors concerning how to optimally utilize adjunctive and novel treatments.
Such factors include consideration of monotherapy vs. add-on adjunctive
treatment; use of medications in drug-naïve vs. already medicated
subjects; combined use ofmedication explicitlywith exposure/extinction
psychotherapy vs. medication taken without explicit psychotherapy;
timing of medication — e.g. at night to aid memory consolidation during
sleep vs. immediately before or after exposure; and use of medications
in countries with well-developed vs. poorly developed health systems.
As the ﬁeld of psychopharmacotherapy matures beyond the models
that it has followed for decades, all of these considerations are important
for newdrug development. For example somemedicationsmay not be as
efﬁcacious in subjects with a history of antidepressant use, as has been
suggested for D-cycloserine (Werner-Seidler & Richardson, 2007). Fur-
thermore, as sleep is increasingly thought to be associatedwith extinction
learning, targetingmedication to enhance thememory consolidation pro-
cess during sleep may be important (Pace-Schott et al., 2012). Finally,
medications which are available readily in generic form and that do not
require specialized adjunctive psychotherapy may be more readily dis-
seminated to locations with less well-developed mental health care sys-
tems than those that are novel, or more expensive, or that may require
specialized combined therapy. Taken together, these considerations re-
mind us that identifying molecular mechanisms and novel drug ap-
proaches to fear regulation is only part of the challenge, and that the
context of the dissemination of such new therapeutics is also of critical
concern.
In summary, based on the evidence outlined in this review, the next
fewyears promise to produce several novel clinical approaches to treating
trauma- and anxiety-related disorders in a more efﬁcient and persistent
way that will most likely lead to enhanced symptom remission. Progress
will depend on translational research approaches and a close interaction
between preclinical and clinical researchers. Fig. 10 outlines how the dif-
ferent levels of understanding, from genetics to epigenetics to neural cir-
cuits, can inform each other as well as how they can be informed across
species due to the high level of convergence of shared fear-related
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Fig. 10. Strategy for translating research from humans to mice and back, focusing on human disorders of fear dysregulation. Rodentmodels of enhanced fear and impaired extinction (in-
duced by genetic or environmental manipulations) closely resemble human symptomatology, particularly the fear dysregulation that occurs in PTSD, panic, and phobic disorders. Using
these models increases the chances of identifying candidate genes for human anxiety disorders by reducing the problems of genetic heterogeneity and a variable environment. It is also
important to study the involvement of these candidate genes in patients, as well as using unbiased genome-wide association studies and genome-wide epigenetic approaches to identify
previously unknown genetic pathways contributing to risk in humans. Subsequently, elucidating the function of the identiﬁed gene and its epigenetic regulation using rodent models as
well as the human population increases our knowledge of the neurobiology of fear disorders, which, at the same time, is necessary to improve themodels. It is also necessary to use rodent
models to test the ability to pharmacologically enhance extinction of fear and diminish fear expression prior to clinical test phases. Arrows demonstrate how the different levels of under-
standing, from genetics to epigenetics to neural circuits, can inform each other, as well as how they can be informed across species due to the high level of convergence of shared fear-
related processing across mammals.
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of compounds to choose from in the growing pharmacological tool box
in this ﬁeld, many of which display minimal side effects, may enable psy-
chiatrists/psychologists to individualize drug treatment according to spe-
ciﬁc symptoms of anxiety disorders, PTSD and OCD. Such options are
expected to further improve treatment outcome and to reduce the
amount of psychotherapy sessions needed, or the duration or intensity
that is required for long-lasting treatment success. As outlined above, ev-
idence is beginning to shape the hypothesis that speciﬁc classes of com-
pounds and cognitive enhancers may be superior to others in their
ability to support long-term fear-inhibiting effects. There is evidence
that the efﬁcacy of different classes of drugs may be distinctly inﬂuenced
by a number of factors including age, gender and other examples of indi-
vidual differences. Hence, future research is warranted in order to inves-
tigate whether speciﬁc drugs used as cognitive enhancers in this ﬁeld
aremore or less appropriate for speciﬁc individuals, conditions and treat-
ment durations. In conclusion, cognitive enhancers present a promising
option to safely augment extinction-based anxiety- and trauma therapy
and to reduce treatment duration, thereby facilitating treatment coher-
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